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1  Supplementary	 ﾠmethods	 ﾠ
1.1  Mathematical	 ﾠmodels	 ﾠ
This	 ﾠsection	 ﾠgives	 ﾠa	 ﾠbrief	 ﾠsummary	 ﾠof	 ﾠthe	 ﾠfeatures	 ﾠof	 ﾠthe	 ﾠtwelve	 ﾠepidemiological	 ﾠmodels	 ﾠincluded	 ﾠin	 ﾠ
this	 ﾠanalysis.	 ﾠOther	 ﾠthan	 ﾠchanges	 ﾠin	 ﾠART	 ﾠeligibility	 ﾠand	 ﾠuptake,	 ﾠmodel	 ﾠprojections	 ﾠdo	 ﾠnot	 ﾠinclude	 ﾠ
other	 ﾠprevention	 ﾠefforts	 ﾠor	 ﾠchanges	 ﾠin	 ﾠrisk	 ﾠbehaviour	 ﾠin	 ﾠfuture	 ﾠprojections.	 ﾠModel	 ﾠprojections	 ﾠof	 ﾠ
population	 ﾠsize,	 ﾠHIV	 ﾠprevalence,	 ﾠHIV	 ﾠincidence,	 ﾠand	 ﾠnumbers	 ﾠon	 ﾠART	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠepidemic	 ﾠ
calibration	 ﾠare	 ﾠpresented	 ﾠin	 ﾠsection	 ﾠ2.1.	 ﾠ
1.1.1  Generalised	 ﾠepidemic	 ﾠsettings	 ﾠ
In	 ﾠthe	 ﾠgeneralised	 ﾠepidemic	 ﾠsettings,	 ﾠall	 ﾠmodels	 ﾠrepresented	 ﾠthe	 ﾠentire	 ﾠadult	 ﾠpopulation,	 ﾠaged	 ﾠ15	 ﾠ
years	 ﾠand	 ﾠolder.	 ﾠFor	 ﾠSouth	 ﾠAfrica	 ﾠand	 ﾠZambia,	 ﾠall	 ﾠmodels	 ﾠwere	 ﾠcalibrated	 ﾠto	 ﾠmatch	 ﾠthe	 ﾠsame	 ﾠ
estimates	 ﾠfor	 ﾠthe	 ﾠsize	 ﾠof	 ﾠthe	 ﾠadult	 ﾠ(aged	 ﾠ15+	 ﾠyears)	 ﾠpopulation,	 ﾠHIV	 ﾠprevalence	 ﾠamong	 ﾠ15–49	 ﾠyear	 ﾠ
olds,	 ﾠand	 ﾠthe	 ﾠnumber	 ﾠadults	 ﾠ(aged	 ﾠ15+	 ﾠyears)	 ﾠon	 ﾠART	 ﾠin	 ﾠmid-ﾭ‐2011	 ﾠin	 ﾠTable	 ﾠS1:	 ﾠ
Table	 ﾠS1:	 ﾠGeneralised	 ﾠepidemic	 ﾠcalibration	 ﾠestimates
1	 ﾠ
	 ﾠ
South	 ﾠAfrica	 ﾠ Zambia	 ﾠ
Age	 ﾠ15+	 ﾠpopulation	 ﾠsize,	 ﾠmid-ﾭ‐2011:	 ﾠ	 ﾠ 35,015,633	 ﾠ 7,010,595	 ﾠ
Age	 ﾠ15–49	 ﾠHIV	 ﾠprevalence,	 ﾠmid-ﾭ‐2011:	 ﾠ 17.3%	 ﾠ 12.5%	 ﾠ
Age	 ﾠ15+	 ﾠnumber	 ﾠon	 ﾠART,	 ﾠmid-ﾭ‐2011:	 ﾠ 1,416,100	 ﾠ 352,258	 ﾠ
	 ﾠ
Seven	 ﾠmodels	 ﾠ(Goals,	 ﾠSTDSIM,	 ﾠEMOD,	 ﾠBBH,	 ﾠPopART,	 ﾠSynthesis,	 ﾠMenzies)	 ﾠsimulate	 ﾠthe	 ﾠnational	 ﾠHIV	 ﾠ
epidemic	 ﾠin	 ﾠSouth	 ﾠAfrica,	 ﾠand	 ﾠfour	 ﾠsimulate	 ﾠthe	 ﾠnational	 ﾠHIV	 ﾠepidemic	 ﾠin	 ﾠZambia	 ﾠ(Goals,	 ﾠEMOD,	 ﾠ
Macha,	 ﾠPopART),	 ﾠwith	 ﾠthree	 ﾠ(Goals,	 ﾠEMOD,	 ﾠPopART)	 ﾠseparately	 ﾠcalibrated	 ﾠto	 ﾠboth	 ﾠsettings.	 ﾠGoals,	 ﾠ
BBH,	 ﾠPopART,	 ﾠMenzies,	 ﾠand	 ﾠMacha	 ﾠare	 ﾠdeterministic	 ﾠcompartmental	 ﾠmodels.	 ﾠSTDSIM,	 ﾠEMOD,	 ﾠand	 ﾠ
Synthesis	 ﾠare	 ﾠindividual-ﾭ‐based	 ﾠmicrosimulation	 ﾠmodels.	 ﾠAll	 ﾠmodels	 ﾠsimulate	 ﾠHIV	 ﾠtransmission	 ﾠ
between	 ﾠtwo	 ﾠsexes	 ﾠexcept	 ﾠMenzies,	 ﾠwhich	 ﾠdoes	 ﾠnot	 ﾠexplicitly	 ﾠdistinguish	 ﾠsexes.	 ﾠGoals,	 ﾠSTDSIM,	 ﾠ
EMOD,	 ﾠand	 ﾠSynthesis	 ﾠinclude	 ﾠage	 ﾠstructure	 ﾠand	 ﾠage-ﾭ‐specific	 ﾠnatural	 ﾠmortality	 ﾠrates,	 ﾠand	 ﾠGoals,	 ﾠ
EMOD,	 ﾠand	 ﾠSynthesis	 ﾠincorporate	 ﾠmore	 ﾠrapid	 ﾠHIV	 ﾠprogression	 ﾠfor	 ﾠolder	 ﾠadults.	 ﾠBBH	 ﾠand	 ﾠMenzies	 ﾠ
assume	 ﾠthat	 ﾠsexual	 ﾠmixing	 ﾠand	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠHIV	 ﾠinfection	 ﾠare	 ﾠhomogenous	 ﾠin	 ﾠthe	 ﾠgeneral	 ﾠpopulation,	 ﾠ
while	 ﾠthe	 ﾠremaining	 ﾠmodels	 ﾠincorporate	 ﾠheterogeneity	 ﾠin	 ﾠsexual	 ﾠrisk	 ﾠamong	 ﾠthe	 ﾠgeneral	 ﾠpopulation	 ﾠ
in	 ﾠdifferent	 ﾠways.	 ﾠ	 ﾠ
In	 ﾠaddition	 ﾠto	 ﾠheterogeneity	 ﾠin	 ﾠsexual	 ﾠmixing	 ﾠin	 ﾠthe	 ﾠgeneral	 ﾠpopulation,	 ﾠfour	 ﾠof	 ﾠthe	 ﾠgeneralised	 ﾠ
epidemic	 ﾠmodels	 ﾠ(Goals,	 ﾠSTDSIM,	 ﾠEMOD,	 ﾠBBH)	 ﾠinclude	 ﾠsome	 ﾠkey	 ﾠpopulations.	 ﾠGoals,	 ﾠSTDSIM,	 ﾠand	 ﾠ
BBH	 ﾠexplicitly	 ﾠmodel	 ﾠHIV	 ﾠtransmission	 ﾠamong	 ﾠFSW.	 ﾠGoals	 ﾠand	 ﾠBBH	 ﾠsimulate	 ﾠHIV	 ﾠtransmission	 ﾠamong	 ﾠ
men	 ﾠwho	 ﾠhave	 ﾠsex	 ﾠwith	 ﾠmen	 ﾠ(MSM),	 ﾠand	 ﾠBBH	 ﾠallows	 ﾠtransmission	 ﾠbetween	 ﾠMSM	 ﾠand	 ﾠheterosexual	 ﾠ
partners	 ﾠof	 ﾠMSM.	 ﾠ	 ﾠ
Goals,	 ﾠSTDSIM,	 ﾠEMOD,	 ﾠBBH,	 ﾠand	 ﾠPopART	 ﾠmodel	 ﾠHIV	 ﾠprogression	 ﾠand	 ﾠtransmission	 ﾠas	 ﾠdiscrete	 ﾠstages.	 ﾠ
For	 ﾠGoals,	 ﾠBBH	 ﾠand	 ﾠPopART	 ﾠthese	 ﾠstages	 ﾠrelate	 ﾠto	 ﾠCD4	 ﾠ>500,	 ﾠCD4	 ﾠ350–500,	 ﾠCD4	 ﾠ200–350,	 ﾠand	 ﾠCD4	 ﾠ
≤200	 ﾠcells/µL,	 ﾠwhile	 ﾠCD4	 ﾠcount	 ﾠdeclines	 ﾠcontinuously	 ﾠafter	 ﾠseroconversion	 ﾠand	 ﾠinfectiousness	 ﾠis	 ﾠ
represented	 ﾠas	 ﾠdiscrete	 ﾠstages	 ﾠrelated	 ﾠto	 ﾠstage	 ﾠof	 ﾠinfection.	 ﾠSynthesis	 ﾠjointly	 ﾠand	 ﾠcontinuously	 ﾠ
models	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠdecline,	 ﾠviral	 ﾠload,	 ﾠand	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠmorbidities,	 ﾠallowing	 ﾠthese	 ﾠmodels	 ﾠto	 ﾠ
consider	 ﾠeligibility	 ﾠfor	 ﾠthose	 ﾠwith	 ﾠCD4	 ﾠ≤500	 ﾠcells/µL.	 ﾠHIV	 ﾠinfectiousness	 ﾠincreases	 ﾠas	 ﾠthe	 ﾠCD4	 ﾠcell	 ﾠ
count/category	 ﾠdeclines	 ﾠand	 ﾠeach	 ﾠalso	 ﾠincorporates	 ﾠa	 ﾠshort	 ﾠperiod	 ﾠof	 ﾠhigh	 ﾠinfectiousness	 ﾠ
immediately	 ﾠafter	 ﾠbecoming	 ﾠinfected.	 ﾠMenzies	 ﾠmodels	 ﾠHIV	 ﾠprogression	 ﾠin	 ﾠstages	 ﾠof	 ﾠCD4	 ﾠ>350,	 ﾠCD4	 ﾠ	 ﾠ 3	 ﾠ
200–350,	 ﾠand	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL.	 ﾠGoals,	 ﾠPopART,	 ﾠand	 ﾠMenzies	 ﾠmodel	 ﾠthe	 ﾠeffect	 ﾠof	 ﾠHIV	 ﾠinfection	 ﾠand	 ﾠ
ART	 ﾠon	 ﾠprogression	 ﾠto	 ﾠactive	 ﾠtuberculosis	 ﾠ(TB)	 ﾠdisease	 ﾠand	 ﾠTB	 ﾠtransmission.	 ﾠ
1.1.2  Concentrated	 ﾠepidemic	 ﾠsettings	 ﾠ
Three	 ﾠmodels–Pruddell,	 ﾠMishra,	 ﾠand	 ﾠIDU-ﾭ‐Manipur–represent	 ﾠdifferent	 ﾠregions	 ﾠand	 ﾠepidemic	 ﾠtypes	 ﾠin	 ﾠ
India.	 ﾠMishra	 ﾠrepresents	 ﾠthe	 ﾠentire	 ﾠadult	 ﾠ(age	 ﾠ>15	 ﾠyears)	 ﾠpopulation	 ﾠof	 ﾠBelgaum,	 ﾠIndia,	 ﾠwhere	 ﾠthe	 ﾠ
HIV	 ﾠepidemic	 ﾠis	 ﾠprimarily	 ﾠdriven	 ﾠsex	 ﾠwork,	 ﾠand	 ﾠin	 ﾠwhich	 ﾠa	 ﾠsuccessful	 ﾠtargeted	 ﾠintervention	 ﾠ
programme	 ﾠamong	 ﾠFSW	 ﾠinitially	 ﾠimplemented	 ﾠthrough	 ﾠthe	 ﾠAvahan	 ﾠintervention	 ﾠprogramme	 ﾠhas	 ﾠ
increased	 ﾠcondom	 ﾠusage	 ﾠand	 ﾠaccess	 ﾠto	 ﾠART	 ﾠamong	 ﾠFSW,	 ﾠand	 ﾠthereby	 ﾠsubstantially	 ﾠreduced	 ﾠHIV	 ﾠ
incidence	 ﾠover	 ﾠthe	 ﾠpast	 ﾠdecade.
2,3	 ﾠMishra	 ﾠstratifies	 ﾠthe	 ﾠpopulation	 ﾠinto	 ﾠhigh	 ﾠand	 ﾠlow	 ﾠvolume	 ﾠFSW,	 ﾠ
former	 ﾠFSW,	 ﾠmale	 ﾠclients	 ﾠof	 ﾠFSW,	 ﾠformer	 ﾠmale	 ﾠclients,	 ﾠand	 ﾠthe	 ﾠremainder	 ﾠof	 ﾠthe	 ﾠgeneral	 ﾠpopulation.	 ﾠ
Mishra	 ﾠcontributes	 ﾠtwo	 ﾠmodel	 ﾠsimulations:	 ﾠone	 ﾠwhich	 ﾠprojects	 ﾠHIV	 ﾠincidence	 ﾠincluding	 ﾠthe	 ﾠ
successful	 ﾠeffects	 ﾠof	 ﾠthe	 ﾠcondom-ﾭ‐based	 ﾠprevention	 ﾠprogramme	 ﾠover	 ﾠthe	 ﾠpast	 ﾠdecade,	 ﾠand	 ﾠa	 ﾠsecond	 ﾠ
in	 ﾠwhich	 ﾠthe	 ﾠepidemic	 ﾠis	 ﾠsimulated	 ﾠassuming	 ﾠthe	 ﾠincrease	 ﾠin	 ﾠcondom	 ﾠusage	 ﾠand	 ﾠART	 ﾠaccess	 ﾠhad	 ﾠnot	 ﾠ
occurred,	 ﾠresulting	 ﾠin	 ﾠhigher	 ﾠHIV	 ﾠincidence,	 ﾠwhich	 ﾠwe	 ﾠrefer	 ﾠto	 ﾠas	 ﾠthe	 ﾠ‘Mishra	 ﾠ–	 ﾠno	 ﾠFSW	 ﾠintervention’	 ﾠ
model.	 ﾠ
Pruddell	 ﾠrepresents	 ﾠa	 ﾠsubset	 ﾠof	 ﾠthe	 ﾠadult	 ﾠpopulation	 ﾠin	 ﾠBangalore,	 ﾠIndia,	 ﾠwhere	 ﾠthe	 ﾠepidemic	 ﾠis	 ﾠ
primarily	 ﾠdrive	 ﾠby	 ﾠFSW	 ﾠand	 ﾠMSM.	 ﾠThe	 ﾠpopulations	 ﾠrepresented	 ﾠinclude	 ﾠcurrent	 ﾠand	 ﾠformer	 ﾠFSW,	 ﾠ
male	 ﾠclients	 ﾠof	 ﾠFSW,	 ﾠand	 ﾠMSM,	 ﾠbut	 ﾠdoes	 ﾠnot	 ﾠinclude	 ﾠthe	 ﾠgeneral	 ﾠpopulation,	 ﾠwho	 ﾠmay	 ﾠbe	 ﾠsexual	 ﾠ
partners	 ﾠof	 ﾠthese	 ﾠpopulations.	 ﾠIt	 ﾠsimulates	 ﾠimmediate	 ﾠART	 ﾠand	 ﾠexpanded	 ﾠaccess	 ﾠfor	 ﾠcurrent	 ﾠFSW	 ﾠand	 ﾠ
MSM,	 ﾠand	 ﾠboth	 ﾠof	 ﾠthese	 ﾠgroups	 ﾠsimultaneously.	 ﾠ	 ﾠ
IDU-ﾭ‐Manipur	 ﾠrepresents	 ﾠa	 ﾠsubset	 ﾠof	 ﾠthe	 ﾠadult	 ﾠpopulation	 ﾠin	 ﾠChurachandpur	 ﾠdistrict	 ﾠin	 ﾠManipur	 ﾠstate,	 ﾠ
where	 ﾠthe	 ﾠepidemic	 ﾠis	 ﾠprimarily	 ﾠdriven	 ﾠby	 ﾠunsafe	 ﾠdrug	 ﾠinjecting.	 ﾠThe	 ﾠpersons	 ﾠrepresented	 ﾠinclude	 ﾠ
high-ﾭ‐activity,	 ﾠlow-ﾭ‐activity,	 ﾠand	 ﾠformer	 ﾠPWID	 ﾠin	 ﾠManipur,	 ﾠand	 ﾠheterosexual	 ﾠsexual	 ﾠpartners	 ﾠof	 ﾠcurrent	 ﾠ
and	 ﾠformer	 ﾠPWID.	 ﾠIDU-ﾭ‐Manipur	 ﾠalso	 ﾠmodels	 ﾠhepatitis	 ﾠC	 ﾠvirus	 ﾠ(HCV)	 ﾠtransmission	 ﾠthrough	 ﾠunsafe	 ﾠ
injecting	 ﾠand	 ﾠHCV-ﾭ‐related	 ﾠliver	 ﾠdisease	 ﾠprogression.	 ﾠThe	 ﾠmodel	 ﾠsimulates	 ﾠthe	 ﾠimpact	 ﾠof	 ﾠimmediate	 ﾠ
ART	 ﾠand	 ﾠexpanded	 ﾠaccess	 ﾠto	 ﾠcurrent	 ﾠPWID	 ﾠand	 ﾠboth	 ﾠcurrent	 ﾠand	 ﾠformer	 ﾠPWID.	 ﾠ
None	 ﾠof	 ﾠthe	 ﾠmodels	 ﾠfor	 ﾠIndia	 ﾠsimulate	 ﾠan	 ﾠART	 ﾠeligibility	 ﾠthreshold	 ﾠof	 ﾠCD4	 ﾠ≤500	 ﾠcells/µL,	 ﾠonly	 ﾠ
immediate	 ﾠeligibility	 ﾠfor	 ﾠkey	 ﾠpopulations	 ﾠcompared	 ﾠto	 ﾠcurrent	 ﾠeligibility	 ﾠguidelines.	 ﾠ
In	 ﾠVietnam,	 ﾠthe	 ﾠPrevtool	 ﾠmodel	 ﾠrepresents	 ﾠthe	 ﾠentire	 ﾠaged	 ﾠ15–49	 ﾠpopulation	 ﾠof	 ﾠVietnam,	 ﾠ
categorised	 ﾠinto	 ﾠeight	 ﾠdistinct	 ﾠgroups:	 ﾠdirect	 ﾠand	 ﾠindirect	 ﾠFSW,	 ﾠmale	 ﾠclients	 ﾠof	 ﾠFSW,	 ﾠMSM,	 ﾠmale	 ﾠand	 ﾠ
female	 ﾠPWID,	 ﾠand	 ﾠthe	 ﾠremaining	 ﾠmales	 ﾠand	 ﾠfemales	 ﾠwho	 ﾠare	 ﾠnot	 ﾠmembers	 ﾠof	 ﾠthese	 ﾠpopulations.	 ﾠThe	 ﾠ
model	 ﾠsimulates	 ﾠimmediate	 ﾠART	 ﾠeligibility	 ﾠwith	 ﾠstatus	 ﾠquo	 ﾠand	 ﾠprioritised	 ﾠexpanded	 ﾠaccess	 ﾠfor	 ﾠeach	 ﾠ
of	 ﾠFSW,	 ﾠMSM,	 ﾠand	 ﾠPWID,	 ﾠand	 ﾠimmediate	 ﾠeligibility	 ﾠand	 ﾠexpanded	 ﾠaccess	 ﾠfor	 ﾠall	 ﾠthree	 ﾠof	 ﾠthese	 ﾠgroups	 ﾠ
simultaneously.	 ﾠIt	 ﾠalso	 ﾠsimulates	 ﾠART	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤500	 ﾠcells/µL	 ﾠfor	 ﾠall	 ﾠadults,	 ﾠwith	 ﾠprioritised	 ﾠ
expanded	 ﾠaccess	 ﾠfor	 ﾠthese	 ﾠthree	 ﾠgroups.	 ﾠ	 ﾠ
	 ﾠ 	 ﾠ	 ﾠ 4	 ﾠ
1.1.3  Model	 ﾠassumptions	 ﾠabout	 ﾠART	 ﾠ
	 ﾠ
HIV	 ﾠinfectiousness	 ﾠ
Table	 ﾠS2	 ﾠsummarises	 ﾠthe	 ﾠassumptions	 ﾠmade	 ﾠby	 ﾠeach	 ﾠmodel	 ﾠabout	 ﾠthe	 ﾠinfectiousness	 ﾠof	 ﾠa	 ﾠtypical	 ﾠHIV-ﾭ‐
positive	 ﾠperson	 ﾠduring	 ﾠeach	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠstage	 ﾠfor	 ﾠpersons	 ﾠon	 ﾠART	 ﾠand	 ﾠnot	 ﾠon	 ﾠART,	 ﾠrelative	 ﾠto	 ﾠthe	 ﾠ
infectiousness	 ﾠof	 ﾠan	 ﾠuntreated	 ﾠperson	 ﾠwith	 ﾠCD4	 ﾠ350–500	 ﾠcells/µL.	 ﾠFor	 ﾠsome	 ﾠmodels	 ﾠ(STDSIM,	 ﾠEMOD,	 ﾠ
Synthesis)	 ﾠCD4	 ﾠcount	 ﾠis	 ﾠnot	 ﾠdirectly	 ﾠrelated	 ﾠto	 ﾠinfectiousness;	 ﾠvalues	 ﾠin	 ﾠthe	 ﾠtable	 ﾠrepresent	 ﾠderived	 ﾠ
approximate	 ﾠvalues	 ﾠfor	 ﾠrelative	 ﾠinfectiousness	 ﾠfor	 ﾠpersons	 ﾠin	 ﾠeach	 ﾠCD4	 ﾠcategory.	 ﾠ
Table	 ﾠS2:	 ﾠHIV	 ﾠinfectiousness	 ﾠrelative	 ﾠto	 ﾠuntreated	 ﾠperson	 ﾠwith	 ﾠCD4	 ﾠ350–500	 ﾠcells/µL	 ﾠ
	 ﾠ Not	 ﾠon	 ﾠART	 ﾠ On	 ﾠART	 ﾠ
Model	 ﾠ Primary	 ﾠ
Infection	 ﾠ









Goals	 ﾠ 15.9	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 4.8	 ﾠ 0.08	 ﾠ 0.08	 ﾠ 0.08	 ﾠ 0.08	 ﾠ
STDSIM	 ﾠ 8.6	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.7	 ﾠ 2.7	 ﾠ 0.10	 ﾠ 0.10	 ﾠ 0.30	 ﾠ 0.75	 ﾠ
EMOD	 ﾠ 26.7	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 7.3	 ﾠ 0.08	 ﾠ 0.08	 ﾠ 0.08	 ﾠ 0.08	 ﾠ
BBH	 ﾠ 9.0	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 7.5	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ
PopART	 ﾠ 26.0	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 2.3	 ﾠ 0.10	 ﾠ 0.10	 ﾠ 0.10	 ﾠ 0.23	 ﾠ
Synthesis
a	 ﾠ 5.9	 ﾠ 0.9	 ﾠ (reference)	 ﾠ 1.2	 ﾠ 1.4	 ﾠ 0.02	 ﾠ 0.05	 ﾠ 0.13	 ﾠ 0.33	 ﾠ
Menzies	 ﾠ N/A	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 7.3	 ﾠ 7.3	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.29	 ﾠ 0.29	 ﾠ
Macha	 ﾠ 27.0	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 3.5	 ﾠ 0.03	 ﾠ 0.03	 ﾠ 0.03	 ﾠ 0.03	 ﾠ
Pruddell	 ﾠ 18.5	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 3.4	 ﾠ 0.05	 ﾠ 0.05	 ﾠ 0.05	 ﾠ 0.05	 ﾠ
Mishra	 ﾠ 5.0	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.4	 ﾠ 5.0	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ
IDU-ﾭ‐
Manipur	 ﾠ
25.0	 ﾠ 1.0	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 7.6	 ﾠ 0.10	 ﾠ 0.10	 ﾠ 0.10	 ﾠ 0.10	 ﾠ
Prevtool	 ﾠ 1.6	 ﾠ 1.6	 ﾠ (reference)	 ﾠ 1.0	 ﾠ 3.8	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ 0.04	 ﾠ
a	 ﾠFor	 ﾠthe	 ﾠSynthesis	 ﾠmodel,	 ﾠHIV	 ﾠinfectiousness	 ﾠis	 ﾠa	 ﾠfunction	 ﾠof	 ﾠindividual	 ﾠHIV	 ﾠviral	 ﾠload,	 ﾠthus	 ﾠthe	 ﾠvalues	 ﾠin	 ﾠthe	 ﾠtable	 ﾠreflect	 ﾠ
the	 ﾠviral	 ﾠload	 ﾠdistribution	 ﾠin	 ﾠthe	 ﾠART	 ﾠ/	 ﾠCD4	 ﾠcategory.	 ﾠThe	 ﾠrates	 ﾠper	 ﾠpartnership	 ﾠper	 ﾠthree	 ﾠmonth	 ﾠperiod	 ﾠare	 ﾠ0.0001	 ﾠ(VL	 ﾠ
<500),	 ﾠ0.01	 ﾠ(VL	 ﾠ500–5,000),	 ﾠ0.03	 ﾠ(VL	 ﾠ5,000–50,000),	 ﾠ0.06	 ﾠ(VL	 ﾠ50,000–500,000),	 ﾠ0.1	 ﾠ(VL	 ﾠ>500,000).	 ﾠViral	 ﾠload	 ﾠfor	 ﾠuntreated	 ﾠ
individuals	 ﾠvaries	 ﾠand	 ﾠincreases	 ﾠas	 ﾠHIV	 ﾠinfection	 ﾠprogresses.	 ﾠFor	 ﾠpersons	 ﾠon	 ﾠART,	 ﾠaround	 ﾠ90%	 ﾠare	 ﾠvirally	 ﾠsuppressed,	 ﾠ
conferring	 ﾠa	 ﾠtransmission	 ﾠrate	 ﾠof	 ﾠ0.0001	 ﾠper	 ﾠ3	 ﾠmonth	 ﾠperiod.	 ﾠ
	 ﾠ 	 ﾠ	 ﾠ 5	 ﾠ
Effect	 ﾠof	 ﾠART	 ﾠon	 ﾠmortality/survival	 ﾠ
Table	 ﾠS3	 ﾠsummarises	 ﾠmodels’	 ﾠassumptions	 ﾠabout	 ﾠthe	 ﾠtherapeutic	 ﾠbenefits	 ﾠof	 ﾠART	 ﾠfor	 ﾠHIV-ﾭ‐positive	 ﾠ
persons	 ﾠwith	 ﾠdifferent	 ﾠcell	 ﾠcounts.	 ﾠ
Table	 ﾠS3:	 ﾠModel	 ﾠassumptions	 ﾠabout	 ﾠthe	 ﾠtherapeutic	 ﾠbenefits	 ﾠof	 ﾠART	 ﾠ
Model	 ﾠ Summary	 ﾠof	 ﾠtherapeutic	 ﾠeffects	 ﾠof	 ﾠART	 ﾠ
Goals	 ﾠ The	 ﾠeffect	 ﾠof	 ﾠART	 ﾠon	 ﾠmortality	 ﾠvaries	 ﾠby	 ﾠage,	 ﾠsex,	 ﾠCD4	 ﾠcount	 ﾠat	 ﾠART	 ﾠinitiation,	 ﾠand	 ﾠduration	 ﾠon	 ﾠART	 ﾠ(<	 ﾠ6	 ﾠmos,	 ﾠ
6-ﾭ‐12	 ﾠmos,	 ﾠ>	 ﾠ12	 ﾠmos).	 ﾠART	 ﾠhas	 ﾠno	 ﾠeffect	 ﾠon	 ﾠmortality	 ﾠfor	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ>500	 ﾠcells/µL.	 ﾠFor	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ
350-ﾭ‐500	 ﾠcells/µL,	 ﾠART	 ﾠhas	 ﾠno	 ﾠeffect	 ﾠon	 ﾠmortality	 ﾠrates	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠyear,	 ﾠand	 ﾠreduces	 ﾠmortality	 ﾠby	 ﾠaround	 ﾠ25%	 ﾠ
thereafter.	 ﾠFor	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ200-ﾭ‐350	 ﾠcells/µL,	 ﾠART	 ﾠreduces	 ﾠmortality	 ﾠby	 ﾠaround	 ﾠ55–85%	 ﾠafter	 ﾠone	 ﾠyear.	 ﾠ
For	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL,	 ﾠART	 ﾠreduces	 ﾠthe	 ﾠmortality	 ﾠrate	 ﾠby	 ﾠ45–80%	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠyear,	 ﾠand	 ﾠby	 ﾠover	 ﾠ
90%	 ﾠthereafter.	 ﾠFull	 ﾠdetails	 ﾠare	 ﾠavailable	 ﾠfrom	 ﾠthe	 ﾠSpectrum	 ﾠmodel:	 ﾠ
http://www.futuresinstitute.org/spectrum.aspx	 ﾠ
STDSIM	 ﾠ Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠprogress	 ﾠthrough	 ﾠsix	 ﾠsymptom-ﾭ‐based	 ﾠstages:	 ﾠacute	 ﾠinfection,	 ﾠtwo	 ﾠ
asymptomatic	 ﾠstages,	 ﾠ2	 ﾠsymptomatic	 ﾠstages,	 ﾠand	 ﾠAIDS.	 ﾠPersons	 ﾠon	 ﾠART	 ﾠprogress	 ﾠthrough	 ﾠthe	 ﾠsame	 ﾠstages	 ﾠas	 ﾠ
uninfected	 ﾠpersons,	 ﾠat	 ﾠa	 ﾠ4	 ﾠtimes	 ﾠslower	 ﾠrate	 ﾠafter	 ﾠinitiating	 ﾠtreatment.	 ﾠ
EMOD	 ﾠ HIV-ﾭ‐positive	 ﾠpersons	 ﾠproceed	 ﾠthrough	 ﾠthree	 ﾠinfectious	 ﾠstages	 ﾠ(acute,	 ﾠasymptomatic,	 ﾠand	 ﾠAIDS),	 ﾠand	 ﾠCD4	 ﾠ
count	 ﾠdeclines	 ﾠlinearly	 ﾠuntil	 ﾠdeath.	 ﾠSurvival	 ﾠafter	 ﾠART	 ﾠinitiation	 ﾠdepends	 ﾠon	 ﾠCD4	 ﾠcount	 ﾠcategory	 ﾠ(25–49,	 ﾠ50–
99,	 ﾠ100–199,	 ﾠ200+	 ﾠcells/µL),	 ﾠage,	 ﾠsex,	 ﾠand	 ﾠpresence	 ﾠof	 ﾠWHO	 ﾠStage	 ﾠIII/IV	 ﾠclinical	 ﾠdisease.	 ﾠThere	 ﾠis	 ﾠno	 ﾠadditional	 ﾠ
survival	 ﾠbenefit	 ﾠfor	 ﾠpersons	 ﾠinitiating	 ﾠCD4	 ﾠ>350	 ﾠcells/µL	 ﾠcompared	 ﾠto	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ200-ﾭ‐350	 ﾠcells/µL.	 ﾠFull	 ﾠ
details	 ﾠare	 ﾠavailable:	 ﾠhttp://arxiv.org/pdf/1206.3720.pdf	 ﾠ
BBH	 ﾠ Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠexperience	 ﾠmortality	 ﾠrates	 ﾠof	 ﾠ0.049	 ﾠper	 ﾠyear	 ﾠ(CD4	 ﾠ>350	 ﾠcells/µL),	 ﾠ0.077	 ﾠper	 ﾠ
year	 ﾠ(CD4	 ﾠ200–350	 ﾠcells/µL),	 ﾠand	 ﾠ0.237	 ﾠper	 ﾠyear	 ﾠ(CD4	 ﾠ≤200	 ﾠcells/µL).	 ﾠThe	 ﾠmortality	 ﾠrate	 ﾠis	 ﾠreduced	 ﾠto	 ﾠ0.027	 ﾠ
per	 ﾠyear	 ﾠfor	 ﾠall	 ﾠpersons	 ﾠon	 ﾠART.	 ﾠ	 ﾠ
PopART	 ﾠ Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠproceed	 ﾠthrough	 ﾠprimary	 ﾠinfection	 ﾠfollowed	 ﾠby	 ﾠfour	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠstages	 ﾠ
(CD4	 ﾠ>500,	 ﾠ350–500,	 ﾠ200–350,	 ﾠ≤200).	 ﾠPersons	 ﾠon	 ﾠART	 ﾠprogress	 ﾠthrough	 ﾠthe	 ﾠsame	 ﾠstages	 ﾠas	 ﾠuninfected	 ﾠ
persons,	 ﾠat	 ﾠa	 ﾠ2	 ﾠtimes	 ﾠslower	 ﾠrate	 ﾠafter	 ﾠinitiating	 ﾠtreatment.	 ﾠ
Synthesis	 ﾠ Risk	 ﾠof	 ﾠmortality	 ﾠdepends	 ﾠon	 ﾠCD4	 ﾠcell	 ﾠcount,	 ﾠviral	 ﾠload,	 ﾠage,	 ﾠand	 ﾠbeing	 ﾠon	 ﾠART.	 ﾠPersons	 ﾠon	 ﾠART	 ﾠexperience	 ﾠa	 ﾠ
20%	 ﾠreduction	 ﾠin	 ﾠmortality	 ﾠcompared	 ﾠto	 ﾠsimilar	 ﾠpersons	 ﾠnot	 ﾠon	 ﾠART,	 ﾠplus	 ﾠadditional	 ﾠreductions	 ﾠ
commensurate	 ﾠwith	 ﾠthe	 ﾠsuppression	 ﾠof	 ﾠviral	 ﾠload.	 ﾠToxicities	 ﾠrelated	 ﾠto	 ﾠspecific	 ﾠantiretroviral	 ﾠdrugs	 ﾠeffect	 ﾠsmall	 ﾠ
additional	 ﾠrisks	 ﾠof	 ﾠmortality	 ﾠ(neophrotoxicity	 ﾠassociated	 ﾠwith	 ﾠtenofovir,	 ﾠpancreatitis	 ﾠassociated	 ﾠwith	 ﾠ
didanosine	 ﾠor	 ﾠstavudine,	 ﾠand	 ﾠlactic	 ﾠacidosis	 ﾠassociated	 ﾠwith	 ﾠdidanosine,	 ﾠstavudine	 ﾠor	 ﾠzidovudine).	 ﾠTaken	 ﾠ
together,	 ﾠthere	 ﾠis	 ﾠa	 ﾠmodest	 ﾠtherapeutic	 ﾠbenefit	 ﾠfor	 ﾠART	 ﾠinitiation	 ﾠat	 ﾠCD4	 ﾠcount	 ﾠof	 ﾠ500	 ﾠcells/µL	 ﾠversus	 ﾠCD4	 ﾠ
count	 ﾠof	 ﾠ350	 ﾠcells/µL	 ﾠ(36%	 ﾠdied	 ﾠafter	 ﾠ20	 ﾠyears	 ﾠvs.	 ﾠ40%	 ﾠdied	 ﾠafter	 ﾠ20	 ﾠyears).	 ﾠ
Menzies	 ﾠ For	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ>350	 ﾠcells/µL,	 ﾠART	 ﾠreduces	 ﾠthe	 ﾠHIV-ﾭ‐specific	 ﾠmortality	 ﾠrate	 ﾠfrom	 ﾠ0.0083	 ﾠper	 ﾠyear	 ﾠfor	 ﾠ
untreated	 ﾠpersons	 ﾠto	 ﾠ0.0080	 ﾠper	 ﾠyear.	 ﾠFor	 ﾠthose	 ﾠwith	 ﾠCD4	 ﾠ200–350	 ﾠcells/µL,	 ﾠART	 ﾠreduces	 ﾠthe	 ﾠmortality	 ﾠrate	 ﾠ
from	 ﾠ0.030	 ﾠper	 ﾠyear	 ﾠto	 ﾠ0.025	 ﾠper	 ﾠyear.	 ﾠFor	 ﾠthose	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL,	 ﾠART	 ﾠreduces	 ﾠthe	 ﾠmortality	 ﾠrate	 ﾠfrom	 ﾠ
0.257	 ﾠper	 ﾠyear	 ﾠto	 ﾠ0.051	 ﾠper	 ﾠyear.	 ﾠAdditional	 ﾠmortality	 ﾠresults	 ﾠfrom	 ﾠTB	 ﾠdisease.	 ﾠTB	 ﾠdisease	 ﾠincidence	 ﾠincreases	 ﾠ
for	 ﾠuntreated	 ﾠpersons	 ﾠat	 ﾠlower	 ﾠCD4	 ﾠcell	 ﾠcounts,	 ﾠand	 ﾠART	 ﾠreduces	 ﾠthe	 ﾠincidence	 ﾠof	 ﾠTB	 ﾠdisease.	 ﾠ	 ﾠ
Macha	 ﾠ Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ>200	 ﾠcells/µL	 ﾠexperience	 ﾠa	 ﾠmortality	 ﾠrate	 ﾠof	 ﾠ0.098	 ﾠper	 ﾠyear.	 ﾠAfter	 ﾠ
initiating	 ﾠART,	 ﾠmortality	 ﾠis	 ﾠreduced	 ﾠto	 ﾠ0.068	 ﾠper	 ﾠyear	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠ3	 ﾠmonths,	 ﾠto	 ﾠ0.051	 ﾠper	 ﾠyear	 ﾠfor	 ﾠthree	 ﾠto	 ﾠsix	 ﾠ
months	 ﾠon	 ﾠART,	 ﾠand	 ﾠ0.041	 ﾠper	 ﾠyear	 ﾠafter	 ﾠsix	 ﾠmonths	 ﾠon	 ﾠART.	 ﾠUntreated	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL	 ﾠ
experience	 ﾠmortality	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.63	 ﾠper	 ﾠyear.	 ﾠAfter	 ﾠART	 ﾠinitiation,	 ﾠmortality	 ﾠis	 ﾠreduced	 ﾠto	 ﾠ0.19	 ﾠper	 ﾠyear,	 ﾠ
0.063	 ﾠper	 ﾠyear,	 ﾠand	 ﾠ0.06	 ﾠper	 ﾠyear	 ﾠfor	 ﾠ<3	 ﾠmonths,	 ﾠ3–6	 ﾠmonths,	 ﾠand	 ﾠ6+	 ﾠmonths	 ﾠon	 ﾠART.	 ﾠ
Pruddell	 ﾠ Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠproceed	 ﾠthrough	 ﾠacute	 ﾠinfection	 ﾠfollowed	 ﾠby	 ﾠthree	 ﾠCD4	 ﾠcount	 ﾠstages	 ﾠ(CD4	 ﾠ
>350,	 ﾠ200–350,	 ﾠ≤200	 ﾠcells/µL).	 ﾠPersons	 ﾠon	 ﾠART	 ﾠproceed	 ﾠthrough	 ﾠthe	 ﾠstages	 ﾠat	 ﾠ1/3	 ﾠthe	 ﾠrate	 ﾠof	 ﾠuntreated	 ﾠ
persons.	 ﾠ	 ﾠ
Mishra	 ﾠ For	 ﾠpersons	 ﾠwith	 ﾠCD4	 ﾠ>350	 ﾠcells/µL,	 ﾠmortality	 ﾠis	 ﾠreduced	 ﾠfrom	 ﾠ0.025	 ﾠper	 ﾠyear	 ﾠfor	 ﾠuntreated	 ﾠpersons	 ﾠto	 ﾠ0.0032	 ﾠ
per	 ﾠyear	 ﾠfor	 ﾠtreated	 ﾠpersons.	 ﾠFor	 ﾠthose	 ﾠwith	 ﾠCD4	 ﾠ200–350	 ﾠcells/µL,	 ﾠmortality	 ﾠis	 ﾠreduced	 ﾠfrom	 ﾠ0.08	 ﾠper	 ﾠyear	 ﾠto	 ﾠ
0.01	 ﾠper	 ﾠyear	 ﾠwhen	 ﾠtreated.	 ﾠFor	 ﾠthose	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL,	 ﾠmortality	 ﾠis	 ﾠreduced	 ﾠfrom	 ﾠ0.5	 ﾠper	 ﾠyear	 ﾠto	 ﾠ0.05	 ﾠ
per	 ﾠyear	 ﾠwhen	 ﾠtreated.	 ﾠFull	 ﾠreductions	 ﾠin	 ﾠmortality	 ﾠare	 ﾠonly	 ﾠrealised	 ﾠafter	 ﾠthe	 ﾠfirst	 ﾠyear;	 ﾠduring	 ﾠthe	 ﾠfirst	 ﾠyear	 ﾠ
on	 ﾠART	 ﾠreductions	 ﾠin	 ﾠmortality	 ﾠare	 ﾠhalf	 ﾠthat	 ﾠultimately	 ﾠachieved.	 ﾠ
IDU-ﾭ‐
Manipur	 ﾠ
Untreated	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠproceed	 ﾠthrough	 ﾠacute	 ﾠinfection	 ﾠfollowed	 ﾠby	 ﾠthree	 ﾠCD4	 ﾠcount	 ﾠstages	 ﾠ(CD4	 ﾠ
>350,	 ﾠ200–350,	 ﾠ≤200	 ﾠcells/µL).	 ﾠPersons	 ﾠon	 ﾠART	 ﾠproceed	 ﾠthrough	 ﾠthe	 ﾠstages	 ﾠat	 ﾠ1/3	 ﾠthe	 ﾠrate	 ﾠof	 ﾠuntreated	 ﾠ
persons.	 ﾠ
Prevtool	 ﾠ HIV	 ﾠpositive	 ﾠpersons	 ﾠexperience	 ﾠmortality	 ﾠrates	 ﾠdepending	 ﾠon	 ﾠtheir	 ﾠCD4	 ﾠcell	 ﾠcount:	 ﾠ0.0005	 ﾠper	 ﾠyear	 ﾠ(CD4	 ﾠ>500	 ﾠ
cells/µL),	 ﾠ0.00128	 ﾠper	 ﾠyear	 ﾠ(CD4	 ﾠ350–500	 ﾠcells/µL),	 ﾠ0.011	 ﾠper	 ﾠyear	 ﾠ(CD4	 ﾠ200–350	 ﾠcells/µL),	 ﾠand	 ﾠ0.5	 ﾠper	 ﾠyear	 ﾠ
(CD4	 ﾠ<	 ﾠ200	 ﾠper	 ﾠyear).	 ﾠPersons	 ﾠon	 ﾠART	 ﾠreconstitute	 ﾠtheir	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠand	 ﾠincrease	 ﾠto	 ﾠhigher	 ﾠCD4	 ﾠcount	 ﾠ
categories,	 ﾠthereby	 ﾠreducing	 ﾠtheir	 ﾠmortality	 ﾠrisk.	 ﾠ	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Retention	 ﾠon	 ﾠART	 ﾠand	 ﾠre-ﾭ‐initiation	 ﾠ
Table	 ﾠS4	 ﾠsummarises	 ﾠmodels’	 ﾠassumptions	 ﾠabout	 ﾠthe	 ﾠtherapeutic	 ﾠbenefits	 ﾠof	 ﾠART	 ﾠfor	 ﾠHIV-ﾭ‐positive	 ﾠ
persons	 ﾠwith	 ﾠdifferent	 ﾠcell	 ﾠcounts.	 ﾠIn	 ﾠthis	 ﾠstudy,	 ﾠmodels	 ﾠdid	 ﾠnot	 ﾠassume	 ﾠthat	 ﾠpersons	 ﾠinitiating	 ﾠART	 ﾠ
with	 ﾠhigher	 ﾠCD4	 ﾠcell	 ﾠcounts	 ﾠhave	 ﾠpoorer	 ﾠadherence	 ﾠor	 ﾠretention.	 ﾠ
Table	 ﾠS4:	 ﾠModel	 ﾠassumptions	 ﾠabout	 ﾠretention	 ﾠon	 ﾠART	 ﾠand	 ﾠre-ﾭ‐initiation	 ﾠon	 ﾠART	 ﾠafter	 ﾠdropping	 ﾠout	 ﾠ
Model	 ﾠ Summary	 ﾠof	 ﾠmodel	 ﾠassumptions	 ﾠabout	 ﾠretention	 ﾠon	 ﾠART	 ﾠ
	 ﾠ
Goals	 ﾠ Model	 ﾠdoes	 ﾠnot	 ﾠexplicitly	 ﾠsimulate	 ﾠdropout	 ﾠfrom	 ﾠART	 ﾠ
	 ﾠ
STDSIM	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.05	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠfrom	 ﾠtreatment	 ﾠ
reinitiate	 ﾠtreatment	 ﾠat	 ﾠhalf	 ﾠthe	 ﾠrate	 ﾠof	 ﾠART	 ﾠnaïve	 ﾠpersons.	 ﾠ
EMOD	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.1	 ﾠper	 ﾠyear.	 ﾠHalf	 ﾠof	 ﾠpersons	 ﾠcan	 ﾠre-ﾭ‐enter	 ﾠcare	 ﾠand	 ﾠreinitiate	 ﾠART	 ﾠ
at	 ﾠthe	 ﾠsame	 ﾠrate	 ﾠas	 ﾠtreatment	 ﾠnaïve	 ﾠindividuals.	 ﾠThe	 ﾠother	 ﾠhalf	 ﾠcan	 ﾠonly	 ﾠre-ﾭ‐initiate	 ﾠwhen	 ﾠexperiencing	 ﾠ
symptoms,	 ﾠor	 ﾠwhen	 ﾠbrought	 ﾠto	 ﾠcare	 ﾠby	 ﾠan	 ﾠHIV-ﾭ‐positive	 ﾠpartner	 ﾠundergoing	 ﾠpre-ﾭ‐ART	 ﾠmonitoring	 ﾠ(which	 ﾠoccurs	 ﾠ
at	 ﾠlow-ﾭ‐levels	 ﾠin	 ﾠthe	 ﾠbaseline	 ﾠmodel	 ﾠcalibration),	 ﾠor	 ﾠwhen	 ﾠattending	 ﾠantenatal	 ﾠcare.	 ﾠ
BBH	 ﾠ Model	 ﾠdoes	 ﾠnot	 ﾠexplicitly	 ﾠsimulate	 ﾠdropout	 ﾠfrom	 ﾠART.	 ﾠ
	 ﾠ
PopART	 ﾠ All	 ﾠpersons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠdropout	 ﾠrate	 ﾠof	 ﾠ0.05	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠof	 ﾠ
treatment	 ﾠreenter	 ﾠcare	 ﾠand	 ﾠreinitiate	 ﾠtreatment	 ﾠat	 ﾠthe	 ﾠsame	 ﾠrate	 ﾠas	 ﾠtreatment	 ﾠnaïve	 ﾠpersons	 ﾠin	 ﾠthe	 ﾠsame	 ﾠCD4	 ﾠ
category.	 ﾠ
Synthesis	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠexperience	 ﾠan	 ﾠannual	 ﾠrate	 ﾠof	 ﾠinterrupting	 ﾠART	 ﾠof	 ﾠ0.08	 ﾠfor	 ﾠpeople	 ﾠwithout	 ﾠtoxicity	 ﾠand	 ﾠoptimal	 ﾠ
adherence,	 ﾠup	 ﾠto	 ﾠ0.32	 ﾠfor	 ﾠpeople	 ﾠwith	 ﾠtoxicities	 ﾠand	 ﾠpoor	 ﾠaverage	 ﾠadherence	 ﾠ(below	 ﾠ50%)	 ﾠ.	 ﾠPeople	 ﾠwho	 ﾠ
interrupted	 ﾠART	 ﾠexperience	 ﾠa	 ﾠ0.4	 ﾠrate	 ﾠper	 ﾠ3	 ﾠmonths	 ﾠof	 ﾠbeing	 ﾠlost	 ﾠfrom	 ﾠcare.	 ﾠThose	 ﾠwho	 ﾠinterrupted	 ﾠART	 ﾠbut	 ﾠ
who	 ﾠare	 ﾠstill	 ﾠin	 ﾠcare	 ﾠexperience	 ﾠ0.4	 ﾠprobability	 ﾠof	 ﾠrestarting	 ﾠtretament	 ﾠwhile	 ﾠpeople	 ﾠlost	 ﾠfrom	 ﾠcare	 ﾠexperience	 ﾠ
a	 ﾠrate	 ﾠof	 ﾠ0.1	 ﾠper	 ﾠ3	 ﾠmonths	 ﾠof	 ﾠreturning	 ﾠto	 ﾠcare.	 ﾠ
Menzies	 ﾠ Model	 ﾠdoes	 ﾠnot	 ﾠexplicitly	 ﾠsimulate	 ﾠdropout	 ﾠfrom	 ﾠART.	 ﾠ
Macha	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.05	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠreinitiate	 ﾠART	 ﾠat	 ﾠthe	 ﾠ
same	 ﾠrate	 ﾠas	 ﾠpersons	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare.	 ﾠ
Pruddell	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.064	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠare	 ﾠeligibile	 ﾠto	 ﾠ
reinitiate	 ﾠtreatment	 ﾠafter	 ﾠtheir	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠfalls	 ﾠbelow	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL,	 ﾠwith	 ﾠthe	 ﾠrate	 ﾠdepending	 ﾠon	 ﾠthe	 ﾠ
symptomatic	 ﾠstage:	 ﾠ0.01	 ﾠper	 ﾠyear	 ﾠfor	 ﾠCD4	 ﾠ≤200	 ﾠand	 ﾠasymptomatic,	 ﾠ0.03	 ﾠper	 ﾠyear	 ﾠfor	 ﾠsymptomatic	 ﾠpre-ﾭ‐AIDS,	 ﾠ
and	 ﾠ0.08	 ﾠper	 ﾠyear	 ﾠfor	 ﾠthose	 ﾠwith	 ﾠAIDS.	 ﾠ
Mishra	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠdiscontinued	 ﾠtreatment	 ﾠor	 ﾠexperienced	 ﾠvirological	 ﾠtreatment	 ﾠfailure	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ7%	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠ
year	 ﾠon	 ﾠtreatment,	 ﾠand	 ﾠ1%	 ﾠper	 ﾠyear	 ﾠthereafter.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠfrom	 ﾠART	 ﾠreinitiate	 ﾠART	 ﾠbased	 ﾠ
on	 ﾠexperience	 ﾠof	 ﾠclinical	 ﾠsymptoms	 ﾠat	 ﾠthe	 ﾠsame	 ﾠrate	 ﾠas	 ﾠART	 ﾠnaïve	 ﾠpersons.	 ﾠ
IDU-ﾭ‐
Manipur	 ﾠ
Persons	 ﾠon	 ﾠART	 ﾠstop	 ﾠtreatment	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.1	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠwho	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠfrom	 ﾠART	 ﾠare	 ﾠnot	 ﾠ
eligible	 ﾠto	 ﾠre-ﾭ‐initiate	 ﾠtreatment	 ﾠuntil	 ﾠthey	 ﾠreach	 ﾠthe	 ﾠAIDS	 ﾠstage.	 ﾠ
Prevtool	 ﾠ Persons	 ﾠon	 ﾠART	 ﾠdropout	 ﾠor	 ﾠdiscontinue	 ﾠtreatment	 ﾠdue	 ﾠto	 ﾠtreatment	 ﾠfailure	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.05	 ﾠper	 ﾠyear.	 ﾠPersons	 ﾠ
who	 ﾠhave	 ﾠdropped	 ﾠout	 ﾠfrom	 ﾠART	 ﾠrecommence	 ﾠART	 ﾠat	 ﾠa	 ﾠrate	 ﾠof	 ﾠ0.07	 ﾠper	 ﾠyear.	 ﾠ
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Adherence	 ﾠand	 ﾠresistance	 ﾠ	 ﾠ
Two	 ﾠmodels,	 ﾠPrevtool	 ﾠand	 ﾠSynthesis,	 ﾠexplicitly	 ﾠmodel	 ﾠviraemia	 ﾠrelated	 ﾠto	 ﾠpoor	 ﾠadherence	 ﾠand	 ﾠthe	 ﾠ
development	 ﾠof	 ﾠresistance	 ﾠ(see	 ﾠSynthesis	 ﾠmodel	 ﾠfor	 ﾠdetails
4.	 ﾠThis	 ﾠviraemia	 ﾠincreases	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠ
clinical	 ﾠprogression	 ﾠand	 ﾠmortality	 ﾠas	 ﾠwell	 ﾠas	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠresistance.	 ﾠOther	 ﾠmodels	 ﾠimplicitly	 ﾠaccount	 ﾠ
for	 ﾠincomplete	 ﾠviral	 ﾠsuppression	 ﾠrelated	 ﾠto	 ﾠpoor	 ﾠadherence	 ﾠor	 ﾠresistance	 ﾠby	 ﾠassuming	 ﾠa	 ﾠpersistent	 ﾠ
low	 ﾠrisk	 ﾠof	 ﾠHIV	 ﾠtransmission	 ﾠfor	 ﾠpersons	 ﾠon	 ﾠART	 ﾠ(Table	 ﾠS2).	 ﾠ
	 ﾠ
Behaviour	 ﾠchange	 ﾠin	 ﾠresponse	 ﾠto	 ﾠART	 ﾠ
Models	 ﾠdid	 ﾠnot	 ﾠassume	 ﾠany	 ﾠchanges	 ﾠin	 ﾠpopulation-ﾭ‐level	 ﾠsexual	 ﾠrisk	 ﾠbehaviour	 ﾠin	 ﾠthe	 ﾠgeneral	 ﾠ
population	 ﾠ(e.g.	 ﾠ‘risk	 ﾠcompensation’)	 ﾠin	 ﾠresponse	 ﾠto	 ﾠearlier	 ﾠART	 ﾠeligibility	 ﾠor	 ﾠexpanded	 ﾠART	 ﾠaccess.	 ﾠ	 ﾠ
Two	 ﾠmodels	 ﾠ(Synthesis	 ﾠand	 ﾠMacha)	 ﾠassumed	 ﾠmodest	 ﾠreductions	 ﾠin	 ﾠsexual	 ﾠrisk	 ﾠbehaviour	 ﾠamong	 ﾠHIV	 ﾠ
positive	 ﾠpersons	 ﾠafter	 ﾠbeing	 ﾠdiagnosed	 ﾠwith	 ﾠHIV.	 ﾠThe	 ﾠother	 ﾠmodels	 ﾠdid	 ﾠnot	 ﾠassume	 ﾠchanges	 ﾠin	 ﾠsexual	 ﾠ
behaviour	 ﾠupon	 ﾠreceiving	 ﾠa	 ﾠpositive	 ﾠHIV	 ﾠdiagnosis.	 ﾠThe	 ﾠSynthesis	 ﾠmodel	 ﾠassumes	 ﾠreceiving	 ﾠa	 ﾠpositive	 ﾠ
HIV	 ﾠdiagnosis	 ﾠreduces	 ﾠthe	 ﾠprobability	 ﾠof	 ﾠhaving	 ﾠcondom-ﾭ‐less	 ﾠsex	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠ6	 ﾠmonths	 ﾠafter	 ﾠdiagnosis	 ﾠ
by	 ﾠ13%	 ﾠwith	 ﾠa	 ﾠprimary	 ﾠpartner	 ﾠand	 ﾠby	 ﾠ17%	 ﾠwith	 ﾠa	 ﾠcasual	 ﾠpartner.	 ﾠAfter	 ﾠthe	 ﾠfirst	 ﾠsix	 ﾠmonths,	 ﾠthe	 ﾠ
reduction	 ﾠis	 ﾠ9%.	 ﾠThe	 ﾠMacha	 ﾠmodel	 ﾠassumes	 ﾠthat	 ﾠthe	 ﾠcontact	 ﾠrate	 ﾠfor	 ﾠHIV-ﾭ‐positive	 ﾠpersons	 ﾠis	 ﾠreduced	 ﾠ
by	 ﾠ18.6%	 ﾠafter	 ﾠreceiving	 ﾠan	 ﾠHIV	 ﾠdiagnosis..	 ﾠ	 ﾠ
Two	 ﾠother	 ﾠmodels	 ﾠ(STDSIM	 ﾠand	 ﾠPruddell)	 ﾠassumed	 ﾠthat	 ﾠHIV	 ﾠpositive	 ﾠpersons	 ﾠin	 ﾠadvanced	 ﾠdisease	 ﾠ
stages	 ﾠhave	 ﾠreduced	 ﾠsexual	 ﾠrisk	 ﾠbehaviour.	 ﾠThe	 ﾠSTDSIM	 ﾠmodel	 ﾠassumes	 ﾠa	 ﾠ50%	 ﾠreduction	 ﾠin	 ﾠthe	 ﾠ
frequency	 ﾠof	 ﾠsexual	 ﾠcontact	 ﾠwithin	 ﾠregular	 ﾠpartnerships	 ﾠfor	 ﾠpersons	 ﾠin	 ﾠthe	 ﾠAIDS	 ﾠstage,	 ﾠwhile	 ﾠPruddell	 ﾠ
assumes	 ﾠcessation	 ﾠof	 ﾠall	 ﾠnew	 ﾠsexual	 ﾠcontacts	 ﾠfor	 ﾠpersons	 ﾠwith	 ﾠsymptomatic	 ﾠAIDS.	 ﾠSexual	 ﾠactivity	 ﾠ
returns	 ﾠto	 ﾠnormal	 ﾠlevels	 ﾠupon	 ﾠART	 ﾠinitiation.	 ﾠ	 ﾠ 	 ﾠ	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1.2  Outputs	 ﾠreported	 ﾠby	 ﾠepidemiological	 ﾠmodels	 ﾠ
Epidemiological	 ﾠmodels	 ﾠreported	 ﾠstandardised	 ﾠoutputs	 ﾠfor	 ﾠeach	 ﾠART	 ﾠeligibility	 ﾠand	 ﾠaccess	 ﾠstrategy	 ﾠ
that	 ﾠwere	 ﾠused	 ﾠfor	 ﾠcalculation	 ﾠof	 ﾠthe	 ﾠincremental	 ﾠcosts	 ﾠand	 ﾠhealth	 ﾠbenefits.	 ﾠAll	 ﾠmodels	 ﾠreported	 ﾠthe	 ﾠ
following	 ﾠoutputs	 ﾠfor	 ﾠthe	 ﾠpopulation	 ﾠat	 ﾠthe	 ﾠmidpoint	 ﾠof	 ﾠeach	 ﾠyear	 ﾠfrom	 ﾠ2014	 ﾠthrough	 ﾠ2033:	 ﾠ
•  The	 ﾠtotal	 ﾠsize	 ﾠof	 ﾠthe	 ﾠadult	 ﾠ(age	 ﾠ15+)	 ﾠpopulation.	 ﾠ
•  The	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠHIV-ﾭ‐	 ﾠadults.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠnot	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ>350	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠnot	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ200–350	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠnot	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ>350	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ200–350	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwith	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV+	 ﾠadults	 ﾠon	 ﾠART	 ﾠ
All	 ﾠmodels	 ﾠalso	 ﾠreported	 ﾠthe	 ﾠfollowing	 ﾠoutputs	 ﾠabout	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠevents	 ﾠoccurring	 ﾠduring	 ﾠthe	 ﾠ
calendar	 ﾠyear	 ﾠ(1	 ﾠJanuary	 ﾠto	 ﾠ31	 ﾠDecember)	 ﾠannually	 ﾠfrom	 ﾠ2014	 ﾠthrough	 ﾠ2033:	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠnew	 ﾠadult	 ﾠHIV	 ﾠinfections.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠinfected	 ﾠadults	 ﾠentering	 ﾠpre-ﾭ‐ART	 ﾠcare.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠHIV	 ﾠdiagnostic	 ﾠtests	 ﾠconducted	 ﾠ(except	 ﾠBBH,	 ﾠPopART,	 ﾠand	 ﾠIDU-ﾭ‐Manipur,	 ﾠsee	 ﾠ
section	 ﾠ1.3.1(c)).	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠadults	 ﾠinitiating	 ﾠART	 ﾠfrom	 ﾠpre-ﾭ‐ART	 ﾠcare.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠadults	 ﾠinitiating	 ﾠART	 ﾠnot	 ﾠfrom	 ﾠpre-ﾭ‐ART	 ﾠcare.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠadult	 ﾠdeaths.	 ﾠ
Midyear	 ﾠpopulation	 ﾠsizes	 ﾠwere	 ﾠused	 ﾠas	 ﾠan	 ﾠapproximation	 ﾠfor	 ﾠperson-ﾭ‐years	 ﾠlived	 ﾠin	 ﾠeach	 ﾠstate	 ﾠfor	 ﾠthe	 ﾠ
calculation	 ﾠof	 ﾠrates.	 ﾠModels	 ﾠwhich	 ﾠsimulated	 ﾠspecific	 ﾠpopulations	 ﾠ(FSW,	 ﾠMSM,	 ﾠPWID)	 ﾠreported	 ﾠthe	 ﾠ
number	 ﾠof	 ﾠdiagnostic	 ﾠtests	 ﾠand	 ﾠnumber	 ﾠof	 ﾠpersons	 ﾠentering	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠwithin	 ﾠeach	 ﾠof	 ﾠthese	 ﾠ
populations.	 ﾠ
Models	 ﾠwhich	 ﾠsimulated	 ﾠTB	 ﾠdisease	 ﾠreported:	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠadults	 ﾠwith	 ﾠTB	 ﾠdisease	 ﾠat	 ﾠmidyear.	 ﾠ
•  The	 ﾠnumber	 ﾠof	 ﾠTB	 ﾠcases	 ﾠtreated	 ﾠduring	 ﾠthe	 ﾠcalendar	 ﾠyear.	 ﾠ
The	 ﾠIDU-ﾭ‐Manipur	 ﾠmodel,	 ﾠwhich	 ﾠalso	 ﾠincluded	 ﾠhepatitis	 ﾠC	 ﾠvirus	 ﾠ(HCV)	 ﾠtransmission	 ﾠamong	 ﾠPWID,	 ﾠ
reported	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠadults	 ﾠinfected	 ﾠwith	 ﾠHCV	 ﾠstratified	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠfollowing	 ﾠdisease	 ﾠ
stages:	 ﾠmild/moderate	 ﾠHCV,	 ﾠcompensated	 ﾠcirrhosis,	 ﾠdecompensated	 ﾠcirrhosis,	 ﾠand	 ﾠhepatic	 ﾠ
carcinoma.	 ﾠThe	 ﾠfollowing	 ﾠdisability	 ﾠweights	 ﾠwere	 ﾠassociated	 ﾠwith	 ﾠthese	 ﾠfour	 ﾠstages:	 ﾠ0.036,	 ﾠ0.123,	 ﾠ
0.194,	 ﾠ0.484.
5	 ﾠNo	 ﾠadditional	 ﾠhealth	 ﾠcosts	 ﾠwere	 ﾠassociated	 ﾠwith	 ﾠHCV	 ﾠinfection	 ﾠdue	 ﾠto	 ﾠthe	 ﾠlack	 ﾠof	 ﾠ
availability	 ﾠof	 ﾠHCV	 ﾠtreatment	 ﾠin	 ﾠthis	 ﾠsetting.	 ﾠ	 ﾠ
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1.3  Estimation	 ﾠof	 ﾠincremental	 ﾠcosts	 ﾠassociated	 ﾠwith	 ﾠART	 ﾠpolicy	 ﾠchanges	 ﾠ
1.3.1  General	 ﾠapproach	 ﾠ
Costs	 ﾠwere	 ﾠassessed	 ﾠincrementally,	 ﾠand	 ﾠany	 ﾠprogramme	 ﾠarea	 ﾠ(or	 ﾠsimilar	 ﾠcategory	 ﾠof	 ﾠresource	 ﾠ
consumption)	 ﾠwhich	 ﾠwas	 ﾠthought	 ﾠto	 ﾠbe	 ﾠunaffected	 ﾠby	 ﾠthe	 ﾠchanges	 ﾠin	 ﾠART	 ﾠpolicy	 ﾠexamined	 ﾠin	 ﾠthis	 ﾠ
analysis	 ﾠwere	 ﾠnot	 ﾠincluded	 ﾠin	 ﾠthe	 ﾠcosting.	 ﾠThe	 ﾠfollowing	 ﾠbroad	 ﾠcategories	 ﾠwere	 ﾠincluded	 ﾠin	 ﾠthe	 ﾠcost	 ﾠ
assessment:	 ﾠ
(a)  service	 ﾠdelivery	 ﾠcosts	 ﾠfor	 ﾠindividuals	 ﾠreceiving	 ﾠART,	 ﾠ
(b)  service	 ﾠdelivery	 ﾠcosts	 ﾠfor	 ﾠindividuals	 ﾠreceiving	 ﾠpre-ﾭ‐ART	 ﾠcare,	 ﾠ
(c)  service	 ﾠdelivery	 ﾠcosts	 ﾠrequired	 ﾠto	 ﾠidentify	 ﾠand	 ﾠlink	 ﾠHIV-ﾭ‐positive	 ﾠindividuals	 ﾠto	 ﾠcare,	 ﾠ	 ﾠ
(d)  cost	 ﾠsavings	 ﾠdue	 ﾠto	 ﾠreduced	 ﾠhealthcare	 ﾠutilisation	 ﾠin	 ﾠthe	 ﾠroutine	 ﾠhealth	 ﾠsystem,	 ﾠand	 ﾠ
(e)  costs	 ﾠof	 ﾠhigher-ﾭ‐level	 ﾠprogrammatic	 ﾠsupport	 ﾠand	 ﾠsupply-ﾭ‐chain	 ﾠmanagement.	 ﾠ
The	 ﾠgeneral	 ﾠframework	 ﾠfor	 ﾠcalculating	 ﾠtotal	 ﾠcosts	 ﾠfor	 ﾠeach	 ﾠof	 ﾠthese	 ﾠareas	 ﾠwas	 ﾠto	 ﾠ(i)	 ﾠdescribe	 ﾠthe	 ﾠ
relevant	 ﾠunits	 ﾠof	 ﾠservice	 ﾠdelivery,	 ﾠ(ii)	 ﾠestimate	 ﾠthe	 ﾠunit	 ﾠcosts	 ﾠfor	 ﾠdelivering	 ﾠthose	 ﾠservices,	 ﾠ(iii)	 ﾠ
estimate	 ﾠthe	 ﾠquantity	 ﾠof	 ﾠservices	 ﾠprovided,	 ﾠand	 ﾠ(iv)	 ﾠcombine	 ﾠthese	 ﾠestimates	 ﾠto	 ﾠcalculate	 ﾠtotal	 ﾠ
service	 ﾠdelivery	 ﾠcosts.	 ﾠ
ART	 ﾠcosts	 ﾠ
ART	 ﾠcosts	 ﾠwere	 ﾠsubdivided	 ﾠinto	 ﾠARV	 ﾠcosts	 ﾠand	 ﾠnon-ﾭ‐ARV	 ﾠcosts.	 ﾠIn	 ﾠgeneral	 ﾠthe	 ﾠmodels	 ﾠin	 ﾠthis	 ﾠanalysis	 ﾠ
did	 ﾠnot	 ﾠmodel	 ﾠthe	 ﾠreceipt	 ﾠof	 ﾠindividual	 ﾠregimens	 ﾠby	 ﾠpatients,	 ﾠand	 ﾠtherefore	 ﾠARV	 ﾠcosts	 ﾠwere	 ﾠmodeled	 ﾠ
as	 ﾠan	 ﾠoverall	 ﾠaverage.	 ﾠUnder	 ﾠeach	 ﾠstrategy,	 ﾠthe	 ﾠtotal	 ﾠcosts	 ﾠof	 ﾠARV	 ﾠdrugs	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠwere	 ﾠ
calculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠperson-ﾭ‐years	 ﾠof	 ﾠART	 ﾠin	 ﾠthat	 ﾠyear	 ﾠ(estimated	 ﾠas	 ﾠART	 ﾠpatient	 ﾠ
volume	 ﾠat	 ﾠmidyear)	 ﾠby	 ﾠthe	 ﾠaverage	 ﾠannual	 ﾠcost	 ﾠof	 ﾠan	 ﾠART	 ﾠregimen.	 ﾠRegimen	 ﾠdistributions,	 ﾠincluding	 ﾠ
both	 ﾠfirst-ﾭ‐	 ﾠand	 ﾠsecond-ﾭ‐line	 ﾠARV	 ﾠregimens,	 ﾠwere	 ﾠbased	 ﾠon	 ﾠreported	 ﾠdata	 ﾠfor	 ﾠeach	 ﾠcountry,	 ﾠthus	 ﾠ
reflecting	 ﾠcurrent	 ﾠprescribing	 ﾠpractices.	 ﾠPrices	 ﾠfor	 ﾠeach	 ﾠregimen	 ﾠwere	 ﾠcalculated	 ﾠusing	 ﾠaverage	 ﾠdrug	 ﾠ
prices	 ﾠobtained	 ﾠfrom	 ﾠthe	 ﾠWHO	 ﾠGlobal	 ﾠPrice	 ﾠReporting	 ﾠSystem
6.	 ﾠThe	 ﾠaverage	 ﾠannual	 ﾠregimen	 ﾠcost	 ﾠ
was	 ﾠcalculated	 ﾠas	 ﾠthe	 ﾠweighted	 ﾠaverage	 ﾠcost	 ﾠacross	 ﾠall	 ﾠfirst-ﾭ‐	 ﾠand	 ﾠsecond-ﾭ‐line	 ﾠregimens.	 ﾠ
Non-ﾭ‐ARV	 ﾠservice	 ﾠdelivery	 ﾠcosts	 ﾠwere	 ﾠsubdivided	 ﾠinto	 ﾠART	 ﾠinitiation	 ﾠcosts	 ﾠand	 ﾠestablished	 ﾠpatient	 ﾠ
costs.	 ﾠUnder	 ﾠeach	 ﾠstrategy,	 ﾠthe	 ﾠART	 ﾠinitiation	 ﾠcosts—accounting	 ﾠfor	 ﾠthe	 ﾠadditional	 ﾠlaboratory	 ﾠtests	 ﾠ
and	 ﾠclinic	 ﾠvisits	 ﾠincurred	 ﾠduring	 ﾠa	 ﾠpatient’s	 ﾠinitial	 ﾠmonths	 ﾠon	 ﾠART—were	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠ
number	 ﾠof	 ﾠindividuals	 ﾠinitiating	 ﾠART	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠby	 ﾠthe	 ﾠART	 ﾠinitiation	 ﾠunit	 ﾠcost,	 ﾠwhich	 ﾠwas	 ﾠ
obtained	 ﾠfrom	 ﾠan	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠavailable	 ﾠcosting	 ﾠdata.	 ﾠFor	 ﾠpatients	 ﾠwho	 ﾠwere	 ﾠnot	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠ
care	 ﾠbefore	 ﾠART	 ﾠinitiation,	 ﾠART	 ﾠinitiation	 ﾠcosts	 ﾠinclude	 ﾠan	 ﾠadditional	 ﾠcost	 ﾠof	 ﾠan	 ﾠHIV	 ﾠdiagnostic	 ﾠtest	 ﾠ
and	 ﾠCD4	 ﾠcell	 ﾠcount	 ﾠmeasurement,	 ﾠwhich	 ﾠwill	 ﾠhave	 ﾠbeen	 ﾠaccounted	 ﾠfor	 ﾠin	 ﾠHIV	 ﾠtesting	 ﾠ&	 ﾠlinkage	 ﾠcosts	 ﾠ
and	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠcosts	 ﾠ(see	 ﾠbelow)	 ﾠfor	 ﾠthose	 ﾠpatients	 ﾠwho	 ﾠinitiate	 ﾠART	 ﾠafter	 ﾠbeing	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare.	 ﾠ
Establish	 ﾠpatient	 ﾠcosts—accounting	 ﾠfor	 ﾠthe	 ﾠregular	 ﾠclinical	 ﾠcare	 ﾠand	 ﾠlaboratory	 ﾠmonitoring	 ﾠreceived	 ﾠ
by	 ﾠART	 ﾠpatients,	 ﾠas	 ﾠwell	 ﾠas	 ﾠall	 ﾠother	 ﾠsite-ﾭ‐level	 ﾠactivities	 ﾠrequired	 ﾠfor	 ﾠthe	 ﾠfunctioning	 ﾠof	 ﾠthe	 ﾠART	 ﾠ
programme—were	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠperson-ﾭ‐years	 ﾠof	 ﾠART	 ﾠin	 ﾠthat	 ﾠyear	 ﾠ
(estimated	 ﾠas	 ﾠART	 ﾠpatient	 ﾠvolume	 ﾠat	 ﾠmidyear)	 ﾠby	 ﾠthe	 ﾠestablished	 ﾠART	 ﾠpatient	 ﾠunit	 ﾠcost,	 ﾠobtained	 ﾠ
from	 ﾠan	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠavailable	 ﾠcosting	 ﾠdata.	 ﾠNon-ﾭ‐ARV	 ﾠservice	 ﾠdelivery	 ﾠcosts	 ﾠwere	 ﾠcalculated	 ﾠ
as	 ﾠthe	 ﾠsum	 ﾠof	 ﾠinitiation	 ﾠand	 ﾠestablish	 ﾠpatient	 ﾠcosts,	 ﾠand	 ﾠtotal	 ﾠART	 ﾠcosts	 ﾠcalculated	 ﾠas	 ﾠthe	 ﾠsum	 ﾠof	 ﾠARV	 ﾠ
and	 ﾠnon-ﾭ‐ARV	 ﾠcosts.	 ﾠ	 ﾠ 10	 ﾠ
Pre-ﾭ‐ART	 ﾠcosts	 ﾠ
Pre-ﾭ‐ART	 ﾠpatients	 ﾠreceive	 ﾠregular	 ﾠclinical	 ﾠand	 ﾠlaboratory	 ﾠmonitoring	 ﾠto	 ﾠassess	 ﾠtheir	 ﾠeligibility	 ﾠfor	 ﾠART	 ﾠ
initiation,	 ﾠas	 ﾠwell	 ﾠas	 ﾠprophylaxis	 ﾠand	 ﾠtreatment	 ﾠof	 ﾠopportunistic	 ﾠinfections,	 ﾠand	 ﾠother	 ﾠHIV	 ﾠcare	 ﾠ
services	 ﾠprovided	 ﾠby	 ﾠthe	 ﾠHIV	 ﾠtreatment	 ﾠprogramme.	 ﾠUnder	 ﾠeach	 ﾠstrategy,	 ﾠthe	 ﾠtotal	 ﾠcosts	 ﾠof	 ﾠpre-ﾭ‐ART	 ﾠ
care	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠwere	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠperson-ﾭ‐years	 ﾠof	 ﾠpre-ﾭ‐ART	 ﾠin	 ﾠthat	 ﾠ
year	 ﾠ(estimated	 ﾠas	 ﾠpre-ﾭ‐ART	 ﾠpatient	 ﾠvolume	 ﾠat	 ﾠmidyear)	 ﾠby	 ﾠthe	 ﾠpre-ﾭ‐ART	 ﾠpatient	 ﾠunit	 ﾠcost,	 ﾠobtained	 ﾠ
from	 ﾠan	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠavailable	 ﾠcosting	 ﾠdata.	 ﾠ
HIV	 ﾠtesting	 ﾠcosts	 ﾠ
The	 ﾠstrategies	 ﾠin	 ﾠthese	 ﾠanalyses	 ﾠfocused	 ﾠon	 ﾠvarious	 ﾠapproaches	 ﾠfor	 ﾠproviding	 ﾠHIV	 ﾠtreatment,	 ﾠand	 ﾠ
some	 ﾠof	 ﾠthese	 ﾠapproaches	 ﾠ(particularly	 ﾠthe	 ﾠexpanded	 ﾠaccess	 ﾠstrategies)	 ﾠrequired	 ﾠa	 ﾠsubstantial	 ﾠ
acceleration	 ﾠin	 ﾠthe	 ﾠrate	 ﾠat	 ﾠwhich	 ﾠHIV-ﾭ‐positive	 ﾠindividuals	 ﾠare	 ﾠidentified	 ﾠfor	 ﾠcare	 ﾠand	 ﾠtreatment.	 ﾠMost	 ﾠ
models	 ﾠincluded	 ﾠmechanistic	 ﾠrepresentations	 ﾠof	 ﾠthe	 ﾠvolume	 ﾠof	 ﾠHIV	 ﾠtesting	 ﾠrequired	 ﾠto	 ﾠachieve	 ﾠthe	 ﾠ
levels	 ﾠof	 ﾠART	 ﾠscale-ﾭ‐up	 ﾠspecified	 ﾠfor	 ﾠeach	 ﾠhealthcare	 ﾠaccess	 ﾠstrategy.	 ﾠFor	 ﾠthose	 ﾠmodels	 ﾠwhich	 ﾠ
reported	 ﾠtesting	 ﾠvolumes	 ﾠ(Goals,	 ﾠSTDSIM,	 ﾠEMOD,	 ﾠSynthesis,	 ﾠMenzies,	 ﾠMacha,	 ﾠPruddell,	 ﾠMishra,	 ﾠand	 ﾠ
Prevtool),	 ﾠtotal	 ﾠtesting	 ﾠcosts	 ﾠfor	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠwere	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠ
individuals	 ﾠreceiving	 ﾠan	 ﾠHIV	 ﾠtest	 ﾠduring	 ﾠthe	 ﾠyear	 ﾠby	 ﾠthe	 ﾠVCT	 ﾠunit	 ﾠcost,	 ﾠwhich	 ﾠwas	 ﾠobtained	 ﾠfrom	 ﾠan	 ﾠ
evidence	 ﾠsynthesis	 ﾠof	 ﾠavailable	 ﾠcosting	 ﾠdata.	 ﾠFor	 ﾠmodels	 ﾠwhich	 ﾠdid	 ﾠnot	 ﾠhave	 ﾠa	 ﾠmechanism	 ﾠfor	 ﾠ
estimating	 ﾠtesting	 ﾠvolume	 ﾠ(BBH,	 ﾠPopART,	 ﾠIDU-ﾭ‐Manipur),	 ﾠwe	 ﾠdeveloped	 ﾠa	 ﾠsimple	 ﾠfunction	 ﾠfor	 ﾠ
estimating	 ﾠtesting	 ﾠcosts	 ﾠbased	 ﾠon	 ﾠ(i)	 ﾠthe	 ﾠrate	 ﾠat	 ﾠwhich	 ﾠHIV-ﾭ‐positive	 ﾠadults	 ﾠwho	 ﾠwere	 ﾠnot	 ﾠin	 ﾠcare	 ﾠ
entered	 ﾠcare	 ﾠin	 ﾠeach	 ﾠyear,	 ﾠ(ii)	 ﾠa	 ﾠmultiplier	 ﾠto	 ﾠaccount	 ﾠfor	 ﾠloss-ﾭ‐to-ﾭ‐follow-ﾭ‐up	 ﾠbetween	 ﾠHIV	 ﾠtesting	 ﾠand	 ﾠ
HIV	 ﾠcare,	 ﾠand	 ﾠ(iii)	 ﾠthe	 ﾠVCT	 ﾠunit	 ﾠcost.	 ﾠWe	 ﾠestimated	 ﾠthe	 ﾠrate	 ﾠof	 ﾠentering	 ﾠcare	 ﾠas	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠpeople	 ﾠ
initiating	 ﾠHIV	 ﾠcare	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠdivided	 ﾠby	 ﾠthe	 ﾠtotal	 ﾠHIV	 ﾠpositive	 ﾠpopulation	 ﾠnot	 ﾠyet	 ﾠreceiving	 ﾠpre-ﾭ‐
ART	 ﾠor	 ﾠART	 ﾠat	 ﾠmidyear.	 ﾠThis	 ﾠrate	 ﾠis	 ﾠmultiplied	 ﾠby	 ﾠthe	 ﾠaverage	 ﾠnumber	 ﾠof	 ﾠdiagnoses	 ﾠper	 ﾠperson	 ﾠ
entering	 ﾠcare,	 ﾠtaken	 ﾠto	 ﾠbe	 ﾠ1.7	 ﾠbased	 ﾠon	 ﾠthe	 ﾠresults	 ﾠof	 ﾠa	 ﾠsystematic	 ﾠreview	 ﾠand	 ﾠmeta-ﾭ‐analysis,
7	 ﾠto	 ﾠ
estimate	 ﾠthe	 ﾠrate	 ﾠof	 ﾠHIV	 ﾠtesting	 ﾠamong	 ﾠpersons	 ﾠliving	 ﾠwith	 ﾠHIV	 ﾠwho	 ﾠare	 ﾠnot	 ﾠin	 ﾠcare.	 ﾠThis	 ﾠtesting	 ﾠrate	 ﾠ
is	 ﾠconverted	 ﾠto	 ﾠan	 ﾠannual	 ﾠprobability	 ﾠof	 ﾠbeing	 ﾠtested	 ﾠfor	 ﾠadults	 ﾠliving	 ﾠwith	 ﾠHIV.	 ﾠIt	 ﾠwas	 ﾠassumed	 ﾠthat	 ﾠ
HIV-ﾭ‐negative	 ﾠadults	 ﾠwere	 ﾠ0.65	 ﾠtimes	 ﾠas	 ﾠlikely	 ﾠto	 ﾠbe	 ﾠtested	 ﾠas	 ﾠinfected	 ﾠadults,
8,9	 ﾠand	 ﾠthe	 ﾠannual	 ﾠ
percentage	 ﾠof	 ﾠHIV-ﾭ‐negative	 ﾠadults	 ﾠtesting	 ﾠwas	 ﾠestimated	 ﾠas	 ﾠthe	 ﾠtesting	 ﾠpercentage	 ﾠof	 ﾠinfected	 ﾠadults	 ﾠ
times	 ﾠthis	 ﾠfactor.	 ﾠThe	 ﾠtotal	 ﾠannual	 ﾠtesting	 ﾠvolume	 ﾠwas	 ﾠobtained	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠadults	 ﾠ
living	 ﾠwith	 ﾠHIV	 ﾠwho	 ﾠare	 ﾠnot	 ﾠon	 ﾠART	 ﾠor	 ﾠin	 ﾠpre-ﾭ‐ART	 ﾠcare	 ﾠand	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠHIV-ﾭ‐negative	 ﾠadults	 ﾠby	 ﾠ
their	 ﾠannual	 ﾠtesting	 ﾠpercentages.	 ﾠTotal	 ﾠtesting	 ﾠcosts	 ﾠfor	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠwere	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠ
the	 ﾠtesting	 ﾠvolume	 ﾠfor	 ﾠthat	 ﾠyear	 ﾠby	 ﾠthe	 ﾠVCT	 ﾠunit	 ﾠcost.	 ﾠFor	 ﾠmodels	 ﾠto	 ﾠwhich	 ﾠthis	 ﾠwas	 ﾠapplied	 ﾠthat	 ﾠ
included	 ﾠkey	 ﾠpopulations	 ﾠ(BBH:	 ﾠFSW,	 ﾠMSM;	 ﾠIDU-ﾭ‐Manipur:	 ﾠPWID),	 ﾠthe	 ﾠrate	 ﾠof	 ﾠtesting	 ﾠwas	 ﾠcalculated	 ﾠ
separately	 ﾠfor	 ﾠthese	 ﾠpopulations	 ﾠand	 ﾠfor	 ﾠthe	 ﾠgeneral	 ﾠpopulation	 ﾠwho	 ﾠwere	 ﾠnot	 ﾠpart	 ﾠof	 ﾠthese	 ﾠ
populations.	 ﾠFor	 ﾠkey	 ﾠpopulations	 ﾠ(FSW,	 ﾠMSM,	 ﾠPWID),	 ﾠan	 ﾠadditional	 ﾠcomponent	 ﾠwas	 ﾠadded	 ﾠto	 ﾠthe	 ﾠ
unit	 ﾠcost	 ﾠto	 ﾠrepresent	 ﾠthe	 ﾠadditional	 ﾠcosts	 ﾠrequired	 ﾠfor	 ﾠoutreach	 ﾠto	 ﾠthese	 ﾠgroups.	 ﾠ
Cost	 ﾠsavings	 ﾠin	 ﾠthe	 ﾠgeneral	 ﾠhealth	 ﾠsystem	 ﾠ
The	 ﾠcost	 ﾠcategories	 ﾠdescribed	 ﾠabove	 ﾠcapture	 ﾠthe	 ﾠcosts	 ﾠincurred	 ﾠwithin	 ﾠan	 ﾠHIV	 ﾠprogramme	 ﾠfor	 ﾠ
identification,	 ﾠcare	 ﾠand	 ﾠtreatment	 ﾠof	 ﾠHIV-ﾭ‐positive	 ﾠindividuals.	 ﾠEven	 ﾠif	 ﾠnot	 ﾠidentified	 ﾠand	 ﾠlinked	 ﾠto	 ﾠan	 ﾠ
HIV	 ﾠtreatment	 ﾠprogramme,	 ﾠan	 ﾠindividual	 ﾠwith	 ﾠHIV	 ﾠwill	 ﾠexhibit	 ﾠgreater	 ﾠhealth	 ﾠcare	 ﾠutilisation,	 ﾠthe	 ﾠ
costs	 ﾠof	 ﾠwhich	 ﾠwill	 ﾠbe	 ﾠeliminated	 ﾠwhen	 ﾠthe	 ﾠindividual	 ﾠbegins	 ﾠreceiving	 ﾠtheir	 ﾠcare	 ﾠfrom	 ﾠan	 ﾠHIV	 ﾠ	 ﾠ 11	 ﾠ
treatment	 ﾠprogramme.	 ﾠThese	 ﾠother	 ﾠcare	 ﾠcosts	 ﾠwere	 ﾠsubdivided	 ﾠinto	 ﾠan	 ﾠannual	 ﾠhealthcare	 ﾠutilisation	 ﾠ
cost	 ﾠand	 ﾠend-ﾭ‐of-ﾭ‐life	 ﾠcare	 ﾠcosts.	 ﾠ	 ﾠ
Annual	 ﾠhealthcare	 ﾠutilisation	 ﾠcosts	 ﾠwere	 ﾠestimated	 ﾠfor	 ﾠthe	 ﾠindividuals	 ﾠwith	 ﾠuntreated	 ﾠHIV	 ﾠ(CD4	 ﾠcell	 ﾠ
count	 ﾠcategories	 ﾠ>350	 ﾠcells/µL	 ﾠ,	 ﾠ200–350	 ﾠcells/µL	 ﾠand	 ﾠ≤200	 ﾠcells/µL).	 ﾠAnnual	 ﾠhealthcare	 ﾠutilisation	 ﾠ
costs	 ﾠfor	 ﾠan	 ﾠindividual	 ﾠwith	 ﾠuntreated,	 ﾠHIV	 ﾠwere	 ﾠestimated	 ﾠfrom	 ﾠannualised	 ﾠfrequencies	 ﾠof	 ﾠ
outpatient	 ﾠvisits	 ﾠand	 ﾠinpatient	 ﾠdays
10	 ﾠadjusted	 ﾠfor	 ﾠthe	 ﾠdifferent	 ﾠrates	 ﾠof	 ﾠopportunistic	 ﾠinfection	 ﾠ
observed	 ﾠwith	 ﾠeach	 ﾠCD4	 ﾠcategory
11–13	 ﾠmultiplied	 ﾠby	 ﾠestimates	 ﾠof	 ﾠthe	 ﾠunit	 ﾠcosts	 ﾠof	 ﾠoutpatient	 ﾠvisits	 ﾠ
and	 ﾠinpatient	 ﾠdays	 ﾠobtained	 ﾠfrom	 ﾠWHO	 ﾠCHOICE
14.	 ﾠUnder	 ﾠeach	 ﾠstrategy,	 ﾠthe	 ﾠtotal	 ﾠhealthcare	 ﾠ
utilisation	 ﾠcosts	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠwere	 ﾠcalculated	 ﾠby	 ﾠmultiplying	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠperson-ﾭ‐years	 ﾠof	 ﾠ
untreated	 ﾠHIV	 ﾠwith	 ﾠCD4	 ﾠ>350	 ﾠcells/µL,	 ﾠCD4	 ﾠ200–350	 ﾠcells/µL,	 ﾠand	 ﾠCD4	 ﾠ≤200	 ﾠcells/µL	 ﾠ(estimated	 ﾠas	 ﾠ
the	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠindividuals	 ﾠin	 ﾠthose	 ﾠcategories	 ﾠat	 ﾠmidyear)	 ﾠby	 ﾠthe	 ﾠannualised	 ﾠcost	 ﾠfor	 ﾠeach	 ﾠof	 ﾠ
these	 ﾠcategories.	 ﾠFor	 ﾠthe	 ﾠsubset	 ﾠof	 ﾠmodels	 ﾠwhich	 ﾠmodelled	 ﾠchanges	 ﾠin	 ﾠTB	 ﾠservice	 ﾠutilisation	 ﾠas	 ﾠa	 ﾠ
function	 ﾠof	 ﾠHIV	 ﾠpolicy	 ﾠ(Goals,	 ﾠEMOD,	 ﾠMenzies),	 ﾠthese	 ﾠchanges	 ﾠin	 ﾠTB	 ﾠcontrol	 ﾠcost	 ﾠwere	 ﾠestimated	 ﾠas	 ﾠ
the	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠindividuals	 ﾠreceiving	 ﾠTB	 ﾠtreatment	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear	 ﾠmultiplied	 ﾠby	 ﾠthe	 ﾠunit	 ﾠcost	 ﾠof	 ﾠa	 ﾠ
course	 ﾠof	 ﾠTB	 ﾠtreatment	 ﾠobtained	 ﾠfrom	 ﾠan	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠavailable	 ﾠcosting	 ﾠdata.	 ﾠ
End-ﾭ‐of-ﾭ‐life	 ﾠcare	 ﾠcosts	 ﾠwere	 ﾠassumed	 ﾠto	 ﾠbe	 ﾠthe	 ﾠsame	 ﾠfor	 ﾠall	 ﾠindividuals.	 ﾠFor	 ﾠeach	 ﾠstrategy,	 ﾠtotal	 ﾠend-ﾭ‐
of-ﾭ‐life	 ﾠcare	 ﾠcosts	 ﾠwere	 ﾠestimated	 ﾠas	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠinpatient	 ﾠdays	 ﾠincurred	 ﾠby	 ﾠHIV	 ﾠpositive	 ﾠindividuals	 ﾠ
in	 ﾠthe	 ﾠ6	 ﾠmonths	 ﾠpreceding	 ﾠdeath,
10	 ﾠmultiplied	 ﾠby	 ﾠthe	 ﾠunit	 ﾠcost	 ﾠper	 ﾠinpatient	 ﾠday	 ﾠobtained	 ﾠfrom	 ﾠ
WHO-ﾭ‐CHOICE
14,	 ﾠmultiplied	 ﾠby	 ﾠthe	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠindividuals	 ﾠdying	 ﾠin	 ﾠa	 ﾠgiven	 ﾠyear.	 ﾠ	 ﾠ
Programmatic	 ﾠsupport	 ﾠand	 ﾠsupply-ﾭ‐chain	 ﾠmanagement	 ﾠ
Programme	 ﾠcosts—the	 ﾠcosts	 ﾠof	 ﾠmanagement,	 ﾠadministration,	 ﾠtraining,	 ﾠM&E	 ﾠand	 ﾠother	 ﾠactivities	 ﾠ
undertaken	 ﾠto	 ﾠsupport	 ﾠdirect	 ﾠservice	 ﾠprovision—are	 ﾠa	 ﾠpoorly	 ﾠunderstood	 ﾠcomponent	 ﾠof	 ﾠHIV	 ﾠ
treatment	 ﾠprogrammes,	 ﾠbut	 ﾠcan	 ﾠrepresent	 ﾠa	 ﾠnon-ﾭ‐trivial	 ﾠfraction	 ﾠof	 ﾠtotal	 ﾠcosts.	 ﾠEstimates	 ﾠof	 ﾠ
programme	 ﾠcosts	 ﾠfor	 ﾠPMTCT	 ﾠservices	 ﾠsuggest	 ﾠthat	 ﾠthese	 ﾠcosts	 ﾠcan	 ﾠrepresent	 ﾠ4–18%	 ﾠof	 ﾠtotal	 ﾠ
programme	 ﾠcosts,	 ﾠand	 ﾠfrom	 ﾠ34–97%	 ﾠof	 ﾠtotal	 ﾠcosts	 ﾠfor	 ﾠHIV	 ﾠeducation	 ﾠservices.
15	 ﾠFor	 ﾠthis	 ﾠthe	 ﾠpurposes	 ﾠ
of	 ﾠthis	 ﾠcosting	 ﾠprogramme	 ﾠcosts	 ﾠwere	 ﾠsubdivided	 ﾠinto	 ﾠsupply-ﾭ‐chain	 ﾠmanagement	 ﾠcosts	 ﾠgeneral	 ﾠ
programmatic	 ﾠsupport.	 ﾠSupply	 ﾠchain	 ﾠmanagement	 ﾠ(SCM)	 ﾠcosts	 ﾠwere	 ﾠestimated	 ﾠas	 ﾠa	 ﾠfixed	 ﾠmark-ﾭ‐up	 ﾠon	 ﾠ
top	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠcosts	 ﾠof	 ﾠARVs,	 ﾠcovering	 ﾠinsurance,	 ﾠtransportation,	 ﾠstorage	 ﾠand	 ﾠdistribution	 ﾠof	 ﾠARV	 ﾠ
drugs	 ﾠas	 ﾠwell	 ﾠas	 ﾠother	 ﾠSCM	 ﾠplanning	 ﾠand	 ﾠmanagement	 ﾠactivities.	 ﾠThis	 ﾠmark-ﾭ‐up	 ﾠwas	 ﾠestimated	 ﾠat	 ﾠ20%	 ﾠ
based	 ﾠon	 ﾠconsultation	 ﾠwith	 ﾠARV	 ﾠsupply	 ﾠchain	 ﾠexperts	 ﾠ(Elliot	 ﾠRaizes	 ﾠ(US	 ﾠCDC),	 ﾠJoel	 ﾠKuritsky	 ﾠ(USAID),	 ﾠ
personal	 ﾠcommunication	 ﾠDecember	 ﾠ14
th	 ﾠ2012).	 ﾠGeneral	 ﾠprogrammatic	 ﾠsupport	 ﾠwas	 ﾠestimated	 ﾠas	 ﾠa	 ﾠ
50%	 ﾠmark-ﾭ‐up	 ﾠon	 ﾠtop	 ﾠof	 ﾠdirect	 ﾠnon-ﾭ‐ARV	 ﾠservice	 ﾠprovision	 ﾠcosts	 ﾠ(i.e.	 ﾠrepresenting	 ﾠ33%	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠ
non-ﾭ‐ARV	 ﾠservice	 ﾠprovision	 ﾠcost)	 ﾠbased	 ﾠon	 ﾠinput	 ﾠof	 ﾠcosting	 ﾠand	 ﾠprogrammatic	 ﾠexperts	 ﾠattending	 ﾠthe	 ﾠ
model	 ﾠharmonisation	 ﾠmeeting	 ﾠheld	 ﾠfor	 ﾠthis	 ﾠproject	 ﾠin	 ﾠLondon,	 ﾠNovember	 ﾠ2012.	 ﾠ
1.3.2  Evidence	 ﾠsynthesis	 ﾠfor	 ﾠunit	 ﾠcost	 ﾠestimates	 ﾠ
A	 ﾠnumber	 ﾠof	 ﾠthe	 ﾠunit	 ﾠcosts	 ﾠused	 ﾠfor	 ﾠthis	 ﾠanalysis	 ﾠwere	 ﾠderived	 ﾠfrom	 ﾠan	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠ
available	 ﾠcosting	 ﾠdata.	 ﾠFor	 ﾠsome	 ﾠcountries,	 ﾠempirical	 ﾠcosting	 ﾠdata	 ﾠwere	 ﾠnot	 ﾠavailable	 ﾠfor	 ﾠall	 ﾠof	 ﾠthe	 ﾠ
different	 ﾠunit	 ﾠcosts	 ﾠneeded	 ﾠfor	 ﾠthe	 ﾠanalysis.	 ﾠIn	 ﾠother	 ﾠcountries,	 ﾠmultiple	 ﾠestimates	 ﾠwere	 ﾠavailable	 ﾠfor	 ﾠ
a	 ﾠgiven	 ﾠunit	 ﾠcost.	 ﾠThis	 ﾠevidence	 ﾠsynthesis	 ﾠadopted	 ﾠa	 ﾠBayesian	 ﾠmeta-ﾭ‐analysis	 ﾠapproach
16,17	 ﾠto	 ﾠpool	 ﾠ
data	 ﾠwithin	 ﾠdata	 ﾠrich	 ﾠsettings,	 ﾠand	 ﾠto	 ﾠprovide	 ﾠreasonable	 ﾠunit	 ﾠcost	 ﾠestimates	 ﾠfor	 ﾠsettings	 ﾠwere	 ﾠ
empirical	 ﾠdata	 ﾠwere	 ﾠnot	 ﾠavailable.	 ﾠEmpirical	 ﾠdata	 ﾠwere	 ﾠgathered	 ﾠfrom	 ﾠcosting	 ﾠstudies	 ﾠconducted	 ﾠin	 ﾠ
the	 ﾠcountries	 ﾠincluded	 ﾠin	 ﾠthis	 ﾠanalysis	 ﾠand	 ﾠsimilar	 ﾠsettings,	 ﾠfrom	 ﾠthe	 ﾠpublished	 ﾠliterature,	 ﾠsummary	 ﾠ	 ﾠ 12	 ﾠ
reports,	 ﾠand	 ﾠfrom	 ﾠunpublished	 ﾠestimates	 ﾠfrom	 ﾠrecently	 ﾠcompleted	 ﾠstudies.	 ﾠEstimates	 ﾠwere	 ﾠinflated	 ﾠ
to	 ﾠ2012	 ﾠprice	 ﾠlevels	 ﾠusing	 ﾠthe	 ﾠGDP	 ﾠdeflator	 ﾠin	 ﾠeach	 ﾠcountry
18	 ﾠand	 ﾠconverted	 ﾠto	 ﾠUS	 ﾠdollars	 ﾠat	 ﾠmarket	 ﾠ
exchange	 ﾠrates.	 ﾠThese	 ﾠadjusted	 ﾠestimates	 ﾠwere	 ﾠcombined	 ﾠin	 ﾠa	 ﾠgeneralised	 ﾠlinear	 ﾠmixed	 ﾠeffects	 ﾠ
regression	 ﾠto	 ﾠcontrol	 ﾠfor	 ﾠdifferences	 ﾠin	 ﾠprice	 ﾠlevel	 ﾠbetween	 ﾠcountries	 ﾠand	 ﾠfor	 ﾠhistorical	 ﾠtime	 ﾠtrends	 ﾠin	 ﾠ
unit	 ﾠcost	 ﾠassociated	 ﾠwith	 ﾠeconomies	 ﾠof	 ﾠscale	 ﾠand	 ﾠprogramme	 ﾠmaturation.	 ﾠWeakly	 ﾠinformative	 ﾠpriors	 ﾠ
were	 ﾠused	 ﾠfor	 ﾠmodel	 ﾠparameters,	 ﾠand	 ﾠthe	 ﾠerror	 ﾠdistribution	 ﾠfor	 ﾠlogged	 ﾠcosts	 ﾠwas	 ﾠbased	 ﾠa	 ﾠt-ﾭ‐
distribution	 ﾠto	 ﾠallow	 ﾠfor	 ﾠoutliers	 ﾠin	 ﾠthe	 ﾠempirical	 ﾠcost	 ﾠestimates.	 ﾠThis	 ﾠanalysis	 ﾠwas	 ﾠused	 ﾠto	 ﾠestimate	 ﾠ
unit	 ﾠcost	 ﾠfor	 ﾠeach	 ﾠservice	 ﾠin	 ﾠeach	 ﾠcountry.	 ﾠPoint	 ﾠestimates	 ﾠand	 ﾠcredible	 ﾠintervals	 ﾠfor	 ﾠall	 ﾠunit	 ﾠcosts,	 ﾠ
including	 ﾠthose	 ﾠderived	 ﾠfrom	 ﾠthe	 ﾠevidence	 ﾠsynthesis,	 ﾠare	 ﾠshown	 ﾠin	 ﾠTable	 ﾠS5.	 ﾠA	 ﾠlist	 ﾠof	 ﾠsources	 ﾠused	 ﾠin	 ﾠ
the	 ﾠevidence	 ﾠsynthesis	 ﾠis	 ﾠgiven	 ﾠin	 ﾠTable	 ﾠS6.	 ﾠ
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Table	 ﾠS5:	 ﾠPosterior	 ﾠmean	 ﾠ(95%	 ﾠcredible	 ﾠinterval)	 ﾠunit	 ﾠcost	 ﾠestimates	 ﾠ(2012	 ﾠUS	 ﾠdollars)	 ﾠ
	 ﾠ
South	 ﾠAfrica	 ﾠ Zambia	 ﾠ India	 ﾠ Vietnam	 ﾠ
ART:	 ﾠARV	 ﾠdrug	 ﾠcosts	 ﾠ 143	 ﾠ(107	 ﾠ-ﾭ‐	 ﾠ179)	 ﾠ 141	 ﾠ(106	 ﾠ-ﾭ‐	 ﾠ176)	 ﾠ 91	 ﾠ(68	 ﾠ-ﾭ‐	 ﾠ114)	 ﾠ 105	 ﾠ(99	 ﾠ-ﾭ‐	 ﾠ165)	 ﾠ
ART:	 ﾠnon-ﾭ‐ARV	 ﾠcosts,	 ﾠinitiation	 ﾠ
(previously	 ﾠreceiving	 ﾠpre-ﾭ‐ART)	 ﾠ
95	 ﾠ(68	 ﾠ-ﾭ‐	 ﾠ125)	 ﾠ 49	 ﾠ(33	 ﾠ-ﾭ‐	 ﾠ65)	 ﾠ 29(19	 ﾠ-ﾭ‐	 ﾠ41)	 ﾠ 45	 ﾠ(35	 ﾠ-ﾭ‐	 ﾠ56)	 ﾠ
ART:	 ﾠnon-ﾭ‐ARV	 ﾠcosts,	 ﾠinitiation	 ﾠ
(previously	 ﾠuntreated	 ﾠpatient)	 ﾠ
126	 ﾠ(88	 ﾠ-ﾭ‐	 ﾠ175)	 ﾠ 65	 ﾠ(42	 ﾠ-ﾭ‐	 ﾠ92)	 ﾠ 38	 ﾠ(25	 ﾠ-ﾭ‐	 ﾠ57)	 ﾠ 59	 ﾠ(45	 ﾠ-ﾭ‐	 ﾠ79)	 ﾠ
ART:	 ﾠnon-ﾭ‐ARV	 ﾠcosts,	 ﾠestablished	 ﾠ
patient	 ﾠ
422	 ﾠ(317	 ﾠ-ﾭ‐	 ﾠ494)	 ﾠ 217	 ﾠ(138	 ﾠ-ﾭ‐	 ﾠ276)	 ﾠ 128	 ﾠ(86	 ﾠ-ﾭ‐	 ﾠ171)	 ﾠ 198	 ﾠ(161	 ﾠ-ﾭ‐	 ﾠ245)	 ﾠ
Pre-ﾭ‐ART:	 ﾠCD4	 ﾠ>	 ﾠ350	 ﾠ 205	 ﾠ(115	 ﾠ-ﾭ‐	 ﾠ281)	 ﾠ 127	 ﾠ(58	 ﾠ-ﾭ‐	 ﾠ182)	 ﾠ 73	 ﾠ(36	 ﾠ-ﾭ‐	 ﾠ112)	 ﾠ 145	 ﾠ(110	 ﾠ-ﾭ‐	 ﾠ186)	 ﾠ
Pre-ﾭ‐ART:	 ﾠCD4	 ﾠ200	 ﾠ-ﾭ‐	 ﾠ350	 ﾠ 238	 ﾠ(142	 ﾠ-ﾭ‐	 ﾠ319)	 ﾠ 139	 ﾠ(69	 ﾠ-ﾭ‐	 ﾠ196)	 ﾠ 81	 ﾠ(43	 ﾠ-ﾭ‐	 ﾠ121)	 ﾠ 150	 ﾠ(114	 ﾠ-ﾭ‐	 ﾠ192)	 ﾠ
Pre-ﾭ‐ART:	 ﾠCD4	 ﾠ<	 ﾠ200	 ﾠ 359	 ﾠ(267	 ﾠ-ﾭ‐	 ﾠ434)	 ﾠ 185	 ﾠ(116	 ﾠ-ﾭ‐	 ﾠ239)	 ﾠ 109	 ﾠ(72	 ﾠ-ﾭ‐	 ﾠ148)	 ﾠ 169	 ﾠ(134	 ﾠ-ﾭ‐	 ﾠ210)	 ﾠ
HIV	 ﾠtesting	 ﾠ 20	 ﾠ(14	 ﾠ-ﾭ‐	 ﾠ26)	 ﾠ 10	 ﾠ(6	 ﾠ-ﾭ‐	 ﾠ14)	 ﾠ 6	 ﾠ(4	 ﾠ-ﾭ‐	 ﾠ9)	 ﾠ 9	 ﾠ(7	 ﾠ-ﾭ‐	 ﾠ12)	 ﾠ
Cost	 ﾠof	 ﾠidentifying	 ﾠhigh	 ﾠrisk	 ﾠ
populations	 ﾠ(FSW,	 ﾠMSM,	 ﾠPWID)	 ﾠ
67	 ﾠ(46	 ﾠ-ﾭ‐	 ﾠ93)	 ﾠ 34	 ﾠ(21	 ﾠ-ﾭ‐	 ﾠ49)	 ﾠ 20	 ﾠ(14	 ﾠ-ﾭ‐	 ﾠ29)	 ﾠ 31	 ﾠ(23	 ﾠ-ﾭ‐	 ﾠ41)	 ﾠ
Healthcare	 ﾠutilisation	 ﾠcost	 ﾠfor	 ﾠHIV	 ﾠ
positive,	 ﾠuntreated,	 ﾠCD4	 ﾠ>	 ﾠ350	 ﾠ
13	 ﾠ(6	 ﾠ-ﾭ‐	 ﾠ20)	 ﾠ 5	 ﾠ(2	 ﾠ-ﾭ‐	 ﾠ8)	 ﾠ 3	 ﾠ(1	 ﾠ-ﾭ‐	 ﾠ5)	 ﾠ 2	 ﾠ(1	 ﾠ-ﾭ‐	 ﾠ3)	 ﾠ
Healthcare	 ﾠutilisation	 ﾠcost	 ﾠfor	 ﾠHIV	 ﾠ
positive,	 ﾠuntreated,	 ﾠCD4	 ﾠ200	 ﾠ-ﾭ‐	 ﾠ350	 ﾠ
46	 ﾠ(33	 ﾠ-ﾭ‐	 ﾠ58)	 ﾠ 17	 ﾠ(13	 ﾠ-ﾭ‐	 ﾠ22)	 ﾠ 11	 ﾠ(8	 ﾠ-ﾭ‐	 ﾠ14)	 ﾠ 7	 ﾠ(5	 ﾠ-ﾭ‐	 ﾠ9)	 ﾠ
Healthcare	 ﾠutilisation	 ﾠcost	 ﾠfor	 ﾠHIV	 ﾠ
positive,	 ﾠuntreated,	 ﾠCD4	 ﾠ<	 ﾠ200	 ﾠ
167	 ﾠ(158	 ﾠ-ﾭ‐	 ﾠ173)	 ﾠ 63	 ﾠ(60	 ﾠ-ﾭ‐	 ﾠ65)	 ﾠ 39	 ﾠ(37	 ﾠ-ﾭ‐	 ﾠ41)	 ﾠ 26	 ﾠ(25	 ﾠ-ﾭ‐	 ﾠ27)	 ﾠ
TB	 ﾠtreatment	 ﾠ 364	 ﾠ(253	 ﾠ-ﾭ‐	 ﾠ499)	 ﾠ 188	 ﾠ(111	 ﾠ-ﾭ‐	 ﾠ273)	 ﾠ 110	 ﾠ(66	 ﾠ-ﾭ‐	 ﾠ166)	 ﾠ 172	 ﾠ(114	 ﾠ-ﾭ‐	 ﾠ245)	 ﾠ
End-ﾭ‐of-ﾭ‐life	 ﾠcare	 ﾠ 160	 ﾠ(68	 ﾠ-ﾭ‐	 ﾠ248)	 ﾠ 50	 ﾠ(21	 ﾠ-ﾭ‐	 ﾠ77)	 ﾠ 34	 ﾠ(15	 ﾠ-ﾭ‐	 ﾠ53)	 ﾠ 32	 ﾠ(13	 ﾠ-ﾭ‐	 ﾠ49)	 ﾠ
Supply	 ﾠchain	 ﾠmanagement	 ﾠ(%,	 ﾠ
multiplier	 ﾠon	 ﾠARV	 ﾠcosts)	 ﾠ
20%	 ﾠ
(15%	 ﾠ-ﾭ‐	 ﾠ25%)	 ﾠ
20%	 ﾠ
(15%	 ﾠ-ﾭ‐	 ﾠ25%)	 ﾠ
20%	 ﾠ
(15%	 ﾠ-ﾭ‐	 ﾠ25%)	 ﾠ
20%	 ﾠ
(15%	 ﾠ-ﾭ‐	 ﾠ25%)	 ﾠ
Programmatic	 ﾠsupport	 ﾠ(%,	 ﾠmultiplier	 ﾠ
on	 ﾠnon-ﾭ‐ARV	 ﾠcosts)	 ﾠ
50%	 ﾠ
(25%	 ﾠ-ﾭ‐	 ﾠ75%)	 ﾠ
50%	 ﾠ
(25%	 ﾠ-ﾭ‐	 ﾠ75%)	 ﾠ
50%	 ﾠ
(25%	 ﾠ-ﾭ‐	 ﾠ75%)	 ﾠ
50%	 ﾠ
(25%	 ﾠ-ﾭ‐	 ﾠ75%)	 ﾠ
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Table	 ﾠS6:	 ﾠSources	 ﾠused	 ﾠfor	 ﾠevidence	 ﾠsynthesis	 ﾠof	 ﾠunit	 ﾠcosts	 ﾠ
Data	 ﾠSource	 ﾠ Countries	 ﾠ Unit	 ﾠCosts	 ﾠ Citation	 ﾠ
Cleary	 ﾠ2006	 ﾠ South	 ﾠAfrica	 ﾠ Established	 ﾠART	 ﾠ
10	 ﾠ
Deghaye	 ﾠ2006	 ﾠ South	 ﾠAfrica	 ﾠ Established	 ﾠART	 ﾠ
19	 ﾠ
John	 ﾠ2006	 ﾠ India	 ﾠ Established	 ﾠART	 ﾠ
20	 ﾠ
McConnel	 ﾠ2006	 ﾠ South	 ﾠAfrica	 ﾠ HIV	 ﾠtesting	 ﾠ
21	 ﾠ
Thielman	 ﾠ2006	 ﾠ Tanzania	 ﾠ HIV	 ﾠtesting	 ﾠ
22	 ﾠ
Bassett	 ﾠ2007	 ﾠ South	 ﾠAfrica	 ﾠ HIV	 ﾠtesting	 ﾠ
23	 ﾠ
Fung	 ﾠ2007	 ﾠ India	 ﾠ Outreach	 ﾠto	 ﾠhigh-ﾭ‐risk	 ﾠgroups	 ﾠ
24	 ﾠ
Harling	 ﾠ2007	 ﾠ South	 ﾠAfrica	 ﾠ Established	 ﾠART	 ﾠ
25	 ﾠ
Dandona	 ﾠ2008	 ﾠ India	 ﾠ Outreach	 ﾠto	 ﾠhigh-ﾭ‐risk	 ﾠgroups,	 ﾠHIV	 ﾠtesting	 ﾠ
26	 ﾠ
Dowdy	 ﾠ2008	 ﾠ South	 ﾠAfrica,	 ﾠBrazil,	 ﾠKenya	 ﾠ TB	 ﾠtreatment	 ﾠ
27	 ﾠ
Hounton	 ﾠ2008	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2  Supplementary	 ﾠresults	 ﾠ
2.1  Baseline	 ﾠmodel	 ﾠcalibration	 ﾠ
The	 ﾠfollowing	 ﾠfigures	 ﾠS1	 ﾠ–	 ﾠS5	 ﾠillustrate	 ﾠthe	 ﾠHIV	 ﾠepidemic	 ﾠprojections	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠsimulation	 ﾠ
assuming	 ﾠcontinuation	 ﾠof	 ﾠART	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠ
	 ﾠ
Figure	 ﾠS1:	 ﾠTotal	 ﾠadult	 ﾠpopulation	 ﾠsize	 ﾠ(in	 ﾠmillions)	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠsimulation,	 ﾠassuming	 ﾠeligibility	 ﾠfor	 ﾠ
CD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠ
	 ﾠ
Figure	 ﾠS2:	 ﾠAdult	 ﾠHIV	 ﾠprevalence	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠsimulation,	 ﾠassuming	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠ
cells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠ
























































































































































































)	 ﾠ 16	 ﾠ
	 ﾠ
Figure	 ﾠS3:	 ﾠAdult	 ﾠHIV	 ﾠincidence	 ﾠrate	 ﾠper	 ﾠ100	 ﾠperson-ﾭ‐years	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠsimulation,	 ﾠassuming	 ﾠ
eligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠ
	 ﾠ
	 ﾠ
Figure	 ﾠS4:	 ﾠThe	 ﾠpercentage	 ﾠof	 ﾠadults	 ﾠliving	 ﾠwith	 ﾠHIV	 ﾠwho	 ﾠare	 ﾠon	 ﾠART	 ﾠfor	 ﾠthe	 ﾠbaseline	 ﾠsimulation,	 ﾠ
assuming	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠ
	 ﾠ 	 ﾠ









































































































































































































)	 ﾠ 17	 ﾠ
2.2  The	 ﾠaccumulation	 ﾠof	 ﾠhealth	 ﾠbenefits	 ﾠand	 ﾠcosts	 ﾠover	 ﾠtime	 ﾠ
The	 ﾠfollowing	 ﾠfigures	 ﾠillustrate	 ﾠhow	 ﾠthe	 ﾠhealth	 ﾠbenefits	 ﾠand	 ﾠcosts	 ﾠof	 ﾠeach	 ﾠstrategy	 ﾠaccumulate	 ﾠover	 ﾠ
time.	 ﾠ
	 ﾠ
Figure	 ﾠS5:	 ﾠAnnual	 ﾠadult	 ﾠmortality	 ﾠrate	 ﾠper	 ﾠ100	 ﾠperson-ﾭ‐years.	 ﾠStrategies	 ﾠrepresented	 ﾠare	 ﾠthe	 ﾠsame	 ﾠas	 ﾠ
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 ﾠ
	 ﾠ
Figure	 ﾠS6:	 ﾠThe	 ﾠadditional	 ﾠlife-ﾭ‐years	 ﾠlived	 ﾠin	 ﾠeach	 ﾠyear	 ﾠ(thousands,	 ﾠundiscounted)	 ﾠcompared	 ﾠto	 ﾠ
baseline	 ﾠstrategy	 ﾠof	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠStrategies	 ﾠ
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 ﾠ
	 ﾠ 	 ﾠ
Figure	 ﾠS7:	 ﾠThe	 ﾠincremental	 ﾠcosts	 ﾠincurred	 ﾠin	 ﾠeach	 ﾠyear	 ﾠ(millions	 ﾠUS$,	 ﾠundiscounted)	 ﾠcompared	 ﾠto	 ﾠ
baseline	 ﾠstrategy	 ﾠof	 ﾠeligibility	 ﾠfor	 ﾠCD4	 ﾠ≤350	 ﾠcells/µL	 ﾠand	 ﾠstatus	 ﾠquo	 ﾠaccess	 ﾠto	 ﾠcare.	 ﾠStrategies	 ﾠ















































































3000 Goals STDSIM EMOD
2015 2020 2025 2030
BBH








2015 2020 2025 2030
Synthesis














2015 2020 2025 2030
EMOD
2015 2020 2025 2030
Macha












2015 2020 2025 2030
Belgaum no
FSW interv.























CD4 <500 eligible, status quo access
all HIV+ eligible, status quo access
CD4 <350 eligible, expanded access
CD4 <500 eligible, expanded access
all HIV+ eligible, expanded access
**All strategies compared to baseline eligibility
for CD4 <350 and status quo access	 ﾠ 20	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2.3  Incremental	 ﾠcost-ﾭ‐effectiveness	 ﾠratios	 ﾠfor	 ﾠvaried	 ﾠtime	 ﾠhorizons	 ﾠand	 ﾠdiscount	 ﾠ
rates	 ﾠ
Table	 ﾠS7:	 ﾠCost	 ﾠper	 ﾠDALY	 ﾠaverted	 ﾠ(2012	 ﾠUS$)	 ﾠcomparing	 ﾠselect	 ﾠstrategies	 ﾠin	 ﾠmodels	 ﾠfor	 ﾠSouth	 ﾠAfrica	 ﾠ
	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 5	 ﾠyears	 ﾠ 10	 ﾠyears	 ﾠ 20	 ﾠyears	 ﾠ
	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ
CD4	 ﾠ≤500,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤350,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $2,073	 ﾠ $2,140	 ﾠ $2,208	 ﾠ $665	 ﾠ $735	 ﾠ $811	 ﾠ $221	 ﾠ $273	 ﾠ $336	 ﾠ
STDSIM	 ﾠ $4,708	 ﾠ $4,791	 ﾠ $4,873	 ﾠ $2,468	 ﾠ $2,620	 ﾠ $2,776	 ﾠ $748	 ﾠ $918	 ﾠ $1,117	 ﾠ
EMOD	 ﾠ $11,358	 ﾠ $11,646	 ﾠ $11,942	 ﾠ $4,156	 ﾠ $4,391	 ﾠ $4,642	 ﾠ $1,328	 ﾠ $1,560	 ﾠ $1,830	 ﾠ
BBH	 ﾠ $3,952	 ﾠ $4,063	 ﾠ $4,175	 ﾠ $1,655	 ﾠ $1,763	 ﾠ $1,879	 ﾠ $740	 ﾠ $839	 ﾠ $956	 ﾠ
PopART	 ﾠ $3,722	 ﾠ $3,771	 ﾠ $3,819	 ﾠ $1,714	 ﾠ $1,830	 ﾠ $1,950	 ﾠ $681	 ﾠ $790	 ﾠ $919	 ﾠ
Synthesis	 ﾠ $4,918	 ﾠ $4,982	 ﾠ $5,046	 ﾠ $2,835	 ﾠ $2,927	 ﾠ $3,025	 ﾠ $1,553	 ﾠ $1,691	 ﾠ $1,843	 ﾠ
All	 ﾠHIV+,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤350,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $4,393	 ﾠ $4,525	 ﾠ $4,658	 ﾠ $1,370	 ﾠ $1,496	 ﾠ $1,630	 ﾠ $345	 ﾠ $438	 ﾠ $552	 ﾠ
STDSIM	 ﾠ $17,571	 ﾠ $17,869	 ﾠ $18,169	 ﾠ $9,530	 ﾠ $10,018	 ﾠ $10,525	 ﾠ $3,243	 ﾠ $3,790	 ﾠ $4,430	 ﾠ
EMOD	 ﾠ $12,319	 ﾠ $12,590	 ﾠ $12,867	 ﾠ $4,548	 ﾠ $4,801	 ﾠ $5,071	 ﾠ $1,436	 ﾠ $1,692	 ﾠ $1,989	 ﾠ
BBH	 ﾠ $4,434	 ﾠ $4,561	 ﾠ $4,690	 ﾠ $1,770	 ﾠ $1,894	 ﾠ $2,027	 ﾠ $689	 ﾠ $795	 ﾠ $922	 ﾠ
PopART	 ﾠ $4,869	 ﾠ $4,920	 ﾠ $4,968	 ﾠ $2,166	 ﾠ $2,334	 ﾠ $2,506	 ﾠ $660	 ﾠ $822	 ﾠ $1,015	 ﾠ
Synthesis	 ﾠ $8,106	 ﾠ $8,223	 ﾠ $8,341	 ﾠ $3,971	 ﾠ $4,131	 ﾠ $4,300	 ﾠ $1,925	 ﾠ $2,133	 ﾠ $2,367	 ﾠ
Menzies	 ﾠ $19,656	 ﾠ $20,120	 ﾠ $20,589	 ﾠ $4,540	 ﾠ $4,910	 ﾠ $5,310	 ﾠ $918	 ﾠ $1,132	 ﾠ $1,394	 ﾠ
CD4	 ﾠ≤350,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $4,123	 ﾠ $4,175	 ﾠ $4,226	 ﾠ $2,596	 ﾠ $2,685	 ﾠ $2,776	 ﾠ $1,502	 ﾠ $1,627	 ﾠ $1,767	 ﾠ
STDSIM	 ﾠ $6,994	 ﾠ $7,127	 ﾠ $7,263	 ﾠ $4,326	 ﾠ $4,492	 ﾠ $4,666	 ﾠ $2,475	 ﾠ $2,701	 ﾠ $2,954	 ﾠ
EMOD	 ﾠ $3,703	 ﾠ $3,749	 ﾠ $3,795	 ﾠ $2,390	 ﾠ $2,477	 ﾠ $2,566	 ﾠ $1,379	 ﾠ $1,505	 ﾠ $1,645	 ﾠ
BBH	 ﾠ $2,433	 ﾠ $2,476	 ﾠ $2,519	 ﾠ $1,617	 ﾠ $1,675	 ﾠ $1,736	 ﾠ $1,110	 ﾠ $1,187	 ﾠ $1,272	 ﾠ
PopART	 ﾠ $3,706	 ﾠ $3,764	 ﾠ $3,823	 ﾠ $2,518	 ﾠ $2,604	 ﾠ $2,692	 ﾠ $1,623	 ﾠ $1,750	 ﾠ $1,890	 ﾠ
Synthesis	 ﾠ $2,912	 ﾠ $2,978	 ﾠ $3,044	 ﾠ $1,844	 ﾠ $1,933	 ﾠ $2,025	 ﾠ $1,291	 ﾠ $1,398	 ﾠ $1,518	 ﾠ
Menzies	 ﾠ $2,688	 ﾠ $2,722	 ﾠ $2,757	 ﾠ $1,531	 ﾠ $1,594	 ﾠ $1,659	 ﾠ $588	 ﾠ $686	 ﾠ $796	 ﾠ
CD4	 ﾠ≤500	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $4,167	 ﾠ $4,227	 ﾠ $4,287	 ﾠ $2,388	 ﾠ $2,486	 ﾠ $2,587	 ﾠ $1,247	 ﾠ $1,371	 ﾠ $1,512	 ﾠ
STDSIM	 ﾠ $6,529	 ﾠ $6,648	 ﾠ $6,769	 ﾠ $3,973	 ﾠ $4,136	 ﾠ $4,305	 ﾠ $2,078	 ﾠ $2,303	 ﾠ $2,556	 ﾠ
EMOD	 ﾠ $4,462	 ﾠ $4,527	 ﾠ $4,592	 ﾠ $2,667	 ﾠ $2,784	 ﾠ $2,906	 ﾠ $1,357	 ﾠ $1,521	 ﾠ $1,705	 ﾠ
BBH	 ﾠ $2,791	 ﾠ $2,848	 ﾠ $2,905	 ﾠ $1,681	 ﾠ $1,755	 ﾠ $1,833	 ﾠ $1,012	 ﾠ $1,104	 ﾠ $1,208	 ﾠ
PopART	 ﾠ $3,757	 ﾠ $3,819	 ﾠ $3,880	 ﾠ $2,281	 ﾠ $2,380	 ﾠ $2,483	 ﾠ $1,251	 ﾠ $1,382	 ﾠ $1,528	 ﾠ
Synthesis	 ﾠ $3,218	 ﾠ $3,287	 ﾠ $3,356	 ﾠ $2,037	 ﾠ $2,134	 ﾠ $2,234	 ﾠ $1,375	 ﾠ $1,497	 ﾠ $1,632	 ﾠ
All	 ﾠHIV+	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $4,775	 ﾠ $4,859	 ﾠ $4,942	 ﾠ $2,438	 ﾠ $2,560	 ﾠ $2,687	 ﾠ $1,110	 ﾠ $1,248	 ﾠ $1,407	 ﾠ
STDSIM	 ﾠ $9,451	 ﾠ $9,624	 ﾠ $9,800	 ﾠ $5,511	 ﾠ $5,755	 ﾠ $6,010	 ﾠ $2,627	 ﾠ $2,961	 ﾠ $3,335	 ﾠ
EMOD	 ﾠ $4,560	 ﾠ $4,629	 ﾠ $4,698	 ﾠ $2,693	 ﾠ $2,816	 ﾠ $2,943	 ﾠ $1,339	 ﾠ $1,508	 ﾠ $1,698	 ﾠ
BBH	 ﾠ $2,905	 ﾠ $2,968	 ﾠ $3,031	 ﾠ $1,688	 ﾠ $1,768	 ﾠ $1,852	 ﾠ $942	 ﾠ $1,040	 ﾠ $1,152	 ﾠ
PopART	 ﾠ $4,127	 ﾠ $4,197	 ﾠ $4,265	 ﾠ $2,253	 ﾠ $2,378	 ﾠ $2,507	 ﾠ $1,000	 ﾠ $1,153	 ﾠ $1,327	 ﾠ
Synthesis	 ﾠ $3,597	 ﾠ $3,677	 ﾠ $3,757	 ﾠ $2,185	 ﾠ $2,297	 ﾠ $2,413	 ﾠ $1,370	 ﾠ $1,514	 ﾠ $1,674	 ﾠ
Menzies	 ﾠ $6,780	 ﾠ $6,875	 ﾠ $6,969	 ﾠ $2,703	 ﾠ $2,874	 ﾠ $3,053	 ﾠ $696	 ﾠ $861	 ﾠ $1,054	 ﾠ
All	 ﾠHIV+,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤500,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $7,729	 ﾠ $7,987	 ﾠ $8,250	 ﾠ $2,034	 ﾠ $2,223	 ﾠ $2,427	 ﾠ $432	 ﾠ $558	 ﾠ $713	 ﾠ
STDSIM	 ﾠ $75,694	 ﾠ $77,895	 ﾠ $80,145	 ﾠ $27,854	 ﾠ $29,729	 ﾠ $31,749	 ﾠ $7,700	 ﾠ $9,088	 ﾠ $10,772	 ﾠ
EMOD	 ﾠ $17,772	 ﾠ $17,824	 ﾠ $17,876	 ﾠ $6,875	 ﾠ $7,225	 ﾠ $7,591	 ﾠ $2,092	 ﾠ $2,498	 ﾠ $2,964	 ﾠ
BBH	 ﾠ $5,604	 ﾠ $5,770	 ﾠ $5,939	 ﾠ $2,033	 ﾠ $2,193	 ﾠ $2,365	 ﾠ $600	 ﾠ $717	 ﾠ $860	 ﾠ
PopART	 ﾠ $6,190	 ﾠ $6,229	 ﾠ $6,265	 ﾠ $2,802	 ﾠ $3,033	 ﾠ $3,264	 ﾠ $629	 ﾠ $870	 ﾠ $1,155	 ﾠ
Synthesis	 ﾠ $18,756	 ﾠ $19,110	 ﾠ $19,468	 ﾠ $6,234	 ﾠ $6,568	 ﾠ $6,927	 ﾠ $2,516	 ﾠ $2,856	 ﾠ $3,249	 ﾠ
CD4	 ﾠ≤500,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠexpanded	 ﾠ
Goals	 ﾠ $4,504	 ﾠ $4,635	 ﾠ $4,766	 ﾠ $1,357	 ﾠ $1,477	 ﾠ $1,607	 ﾠ $309	 ﾠ $401	 ﾠ $512	 ﾠ
STDSIM	 ﾠ $4,818	 ﾠ $4,899	 ﾠ $4,980	 ﾠ $2,455	 ﾠ $2,619	 ﾠ $2,786	 ﾠ $585	 ﾠ $788	 ﾠ $1,022	 ﾠ
EMOD	 ﾠ $21,838	 ﾠ $22,397	 ﾠ $22,956	 ﾠ $8,315	 ﾠ $9,111	 ﾠ $9,944	 ﾠ $981	 ﾠ $1,814	 ﾠ $2,791	 ﾠ
BBH	 ﾠ $4,928	 ﾠ $5,080	 ﾠ $5,233	 ﾠ $1,941	 ﾠ $2,086	 ﾠ $2,243	 ﾠ $750	 ﾠ $872	 ﾠ $1,017	 ﾠ
PopART	 ﾠ $3,997	 ﾠ $4,072	 ﾠ $4,144	 ﾠ $1,440	 ﾠ $1,576	 ﾠ $1,718	 ﾠ $410	 ﾠ $509	 ﾠ $632	 ﾠ
Synthesis	 ﾠ $10,421	 ﾠ $10,518	 ﾠ $10,614	 ﾠ $5,721	 ﾠ $6,010	 ﾠ $6,305	 ﾠ $2,445	 ﾠ $2,815	 ﾠ $3,235	 ﾠ
All	 ﾠHIV+,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠexpanded	 ﾠ
Goals	 ﾠ $7,648	 ﾠ $7,901	 ﾠ $8,158	 ﾠ $2,017	 ﾠ $2,220	 ﾠ $2,439	 ﾠ $378	 ﾠ $516	 ﾠ $686	 ﾠ
STDSIM	 ﾠ $17,058	 ﾠ $17,313	 ﾠ $17,570	 ﾠ $9,472	 ﾠ $9,960	 ﾠ $10,460	 ﾠ $3,032	 ﾠ $3,666	 ﾠ $4,397	 ﾠ
EMOD	 ﾠ $22,832	 ﾠ $23,495	 ﾠ $24,159	 ﾠ $8,260	 ﾠ $9,103	 ﾠ $9,990	 ﾠ $720	 ﾠ $1,561	 ﾠ $2,555	 ﾠ
BBH	 ﾠ $4,822	 ﾠ $4,976	 ﾠ $5,133	 ﾠ $1,889	 ﾠ $2,037	 ﾠ $2,197	 ﾠ $641	 ﾠ $764	 ﾠ $912	 ﾠ
PopART	 ﾠ $5,232	 ﾠ $5,313	 ﾠ $5,390	 ﾠ $1,663	 ﾠ $1,873	 ﾠ $2,091	 ﾠ $127	 ﾠ $277	 ﾠ $463	 ﾠ
Synthesis	 ﾠ $22,301	 ﾠ $22,824	 ﾠ $23,340	 ﾠ $6,833	 ﾠ $7,423	 ﾠ $8,057	 ﾠ $1,974	 ﾠ $2,461	 ﾠ $3,043	 ﾠ
Menzies	 ﾠ $20,421	 ﾠ $20,867	 ﾠ $21,316	 ﾠ $4,582	 ﾠ $4,986	 ﾠ $5,421	 ﾠ $794	 ﾠ $1,024	 ﾠ $1,308	 ﾠ
All	 ﾠHIV+,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤500	 ﾠexpanded	 ﾠ
Goals	 ﾠ $11,900	 ﾠ $12,340	 ﾠ $12,790	 ﾠ $2,780	 ﾠ $3,083	 ﾠ $3,412	 ﾠ $449	 ﾠ $636	 ﾠ $867	 ﾠ
STDSIM	 ﾠ $82,898	 ﾠ $84,726	 ﾠ $86,580	 ﾠ $34,080	 ﾠ $36,270	 ﾠ $38,586	 ﾠ $8,876	 ﾠ $10,809	 ﾠ $13,135	 ﾠ
EMOD	 ﾠ $36,267	 ﾠ $38,699	 ﾠ $41,267	 ﾠ $7,774	 ﾠ $9,030	 ﾠ $10,419	 ﾠ A	 ﾠ A	 ﾠ $733	 ﾠ
BBH	 ﾠ $4,594	 ﾠ $4,755	 ﾠ $4,918	 ﾠ $1,767	 ﾠ $1,923	 ﾠ $2,091	 ﾠ $422	 ﾠ $544	 ﾠ $694	 ﾠ
PopART	 ﾠ $6,793	 ﾠ $6,857	 ﾠ $6,915	 ﾠ $2,037	 ﾠ $2,364	 ﾠ $2,693	 ﾠ A	 ﾠ A	 ﾠ $189	 ﾠ
Synthesis	 ﾠ B	 ﾠ B	 ﾠ B	 ﾠ $9,622	 ﾠ $11,241	 ﾠ $13,208	 ﾠ $1,266	 ﾠ $1,901	 ﾠ $2,720	 ﾠ
‘A’	 ﾠindicates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠfirst	 ﾠdominates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠsecond	 ﾠ(i.e.	 ﾠlower	 ﾠcost,	 ﾠgreater	 ﾠhealth	 ﾠbenefits).	 ﾠ‘B’	 ﾠ
indicates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠsecond	 ﾠdominates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠfirst.	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 21	 ﾠ
Table	 ﾠS8:	 ﾠCost	 ﾠper	 ﾠDALY	 ﾠaverted	 ﾠ(2012	 ﾠUS$)	 ﾠcomparing	 ﾠselected	 ﾠstrategies	 ﾠin	 ﾠmodels	 ﾠfor	 ﾠ
Zambia	 ﾠ
	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 5	 ﾠyears	 ﾠ 10	 ﾠyears	 ﾠ 20	 ﾠyears	 ﾠ
	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ
CD4	 ﾠ≤500,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤350,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $1,253	 ﾠ $1,296	 ﾠ $1,339	 ﾠ $230	 ﾠ $290	 ﾠ $354	 ﾠ A	 ﾠ A	 ﾠ A	 ﾠ
EMOD	 ﾠ $5,448	 ﾠ $5,567	 ﾠ $5,687	 ﾠ $2,266	 ﾠ $2,406	 ﾠ $2,555	 ﾠ $595	 ﾠ $749	 ﾠ $926	 ﾠ
Macha	 ﾠ $1,270	 ﾠ $1,303	 ﾠ $1,336	 ﾠ $446	 ﾠ $477	 ﾠ $510	 ﾠ $105	 ﾠ $131	 ﾠ $163	 ﾠ
PopART	 ﾠ $2,301	 ﾠ $2,349	 ﾠ $2,397	 ﾠ $936	 ﾠ $1,002	 ﾠ $1,071	 ﾠ $311	 ﾠ $364	 ﾠ $429	 ﾠ
All	 ﾠHIV+,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤350,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $2,612	 ﾠ $2,690	 ﾠ $2,768	 ﾠ $706	 ﾠ $802	 ﾠ $903	 ﾠ A	 ﾠ A	 ﾠ $77	 ﾠ
EMOD	 ﾠ $6,530	 ﾠ $6,681	 ﾠ $6,835	 ﾠ $2,535	 ﾠ $2,700	 ﾠ $2,876	 ﾠ $620	 ﾠ $790	 ﾠ $988	 ﾠ
Macha	 ﾠ $1,229	 ﾠ $1,262	 ﾠ $1,295	 ﾠ $433	 ﾠ $464	 ﾠ $497	 ﾠ $101	 ﾠ $128	 ﾠ $159	 ﾠ
PopART	 ﾠ $3,653	 ﾠ $3,751	 ﾠ $3,849	 ﾠ $1,134	 ﾠ $1,247	 ﾠ $1,368	 ﾠ $160	 ﾠ $237	 ﾠ $333	 ﾠ
CD4	 ﾠ≤350,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $5,227	 ﾠ $5,282	 ﾠ $5,336	 ﾠ $3,687	 ﾠ $3,788	 ﾠ $3,891	 ﾠ $2,333	 ﾠ $2,493	 ﾠ $2,670	 ﾠ
EMOD	 ﾠ $4,383	 ﾠ $4,436	 ﾠ $4,489	 ﾠ $2,834	 ﾠ $2,927	 ﾠ $3,024	 ﾠ $1,708	 ﾠ $1,836	 ﾠ $1,980	 ﾠ
Macha	 ﾠ $2,574	 ﾠ $2,601	 ﾠ $2,628	 ﾠ $1,757	 ﾠ $1,809	 ﾠ $1,862	 ﾠ $1,114	 ﾠ $1,193	 ﾠ $1,281	 ﾠ
PopART	 ﾠ $3,043	 ﾠ $3,089	 ﾠ $3,136	 ﾠ $2,106	 ﾠ $2,173	 ﾠ $2,243	 ﾠ $1,336	 ﾠ $1,436	 ﾠ $1,546	 ﾠ
CD4	 ﾠ≤500	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $4,161	 ﾠ $4,221	 ﾠ $4,280	 ﾠ $2,517	 ﾠ $2,614	 ﾠ $2,715	 ﾠ $1,365	 ﾠ $1,495	 ﾠ $1,643	 ﾠ
EMOD	 ﾠ $4,852	 ﾠ $4,925	 ﾠ $4,997	 ﾠ $2,778	 ﾠ $2,900	 ﾠ $3,026	 ﾠ $1,337	 ﾠ $1,496	 ﾠ $1,676	 ﾠ
Macha	 ﾠ $2,043	 ﾠ $2,079	 ﾠ $2,114	 ﾠ $1,021	 ﾠ $1,072	 ﾠ $1,125	 ﾠ $433	 ﾠ $489	 ﾠ $555	 ﾠ
PopART	 ﾠ $3,038	 ﾠ $3,098	 ﾠ $3,159	 ﾠ $1,606	 ﾠ $1,690	 ﾠ $1,778	 ﾠ $705	 ﾠ $796	 ﾠ $902	 ﾠ
All	 ﾠHIV+,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠstatus	 ﾠquo	 ﾠ
Goals	 ﾠ $4,240	 ﾠ $4,317	 ﾠ $4,395	 ﾠ $2,165	 ﾠ $2,279	 ﾠ $2,398	 ﾠ $942	 ﾠ $1,073	 ﾠ $1,224	 ﾠ
EMOD	 ﾠ $4,953	 ﾠ $5,031	 ﾠ $5,109	 ﾠ $2,764	 ﾠ $2,892	 ﾠ $3,024	 ﾠ $1,273	 ﾠ $1,437	 ﾠ $1,622	 ﾠ
Macha	 ﾠ $1,970	 ﾠ $2,006	 ﾠ $2,041	 ﾠ $970	 ﾠ $1,020	 ﾠ $1,072	 ﾠ $406	 ﾠ $460	 ﾠ $523	 ﾠ
PopART	 ﾠ $3,467	 ﾠ $3,554	 ﾠ $3,642	 ﾠ $1,404	 ﾠ $1,516	 ﾠ $1,635	 ﾠ $331	 ﾠ $431	 ﾠ $551	 ﾠ
All	 ﾠHIV+,	 ﾠstatus	 ﾠ
quo	 ﾠvs.	 ﾠCD4	 ﾠ≤500,	 ﾠ
status	 ﾠquo	 ﾠ
Goals	 ﾠ $4,534	 ﾠ $4,678	 ﾠ $4,823	 ﾠ $1,160	 ﾠ $1,298	 ﾠ $1,447	 ﾠ A	 ﾠ $57	 ﾠ $186	 ﾠ
EMOD	 ﾠ $39,639	 ﾠ $42,346	 ﾠ $45,317	 ﾠ $5,139	 ﾠ $5,618	 ﾠ $6,149	 ﾠ $788	 ﾠ $1,080	 ﾠ $1,436	 ﾠ
Macha	 ﾠ $979	 ﾠ $1,012	 ﾠ $1,046	 ﾠ $336	 ﾠ $367	 ﾠ $401	 ﾠ $71	 ﾠ $96	 ﾠ $127	 ﾠ
PopART	 ﾠ $6,260	 ﾠ $6,474	 ﾠ $6,692	 ﾠ $1,449	 ﾠ $1,642	 ﾠ $1,849	 ﾠ A	 ﾠ $69	 ﾠ $205	 ﾠ
CD4	 ﾠ≤500,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠexpanded	 ﾠ
Goals	 ﾠ $1,623	 ﾠ $1,674	 ﾠ $1,726	 ﾠ $373	 ﾠ $435	 ﾠ $500	 ﾠ A	 ﾠ A	 ﾠ A	 ﾠ
EMOD	 ﾠ $7,415	 ﾠ $7,610	 ﾠ $7,806	 ﾠ $2,519	 ﾠ $2,771	 ﾠ $3,037	 ﾠ A	 ﾠ $160	 ﾠ $455	 ﾠ
Macha	 ﾠ $1,317	 ﾠ $1,352	 ﾠ $1,387	 ﾠ $426	 ﾠ $460	 ﾠ $496	 ﾠ $80	 ﾠ $108	 ﾠ $141	 ﾠ
PopART	 ﾠ $3,025	 ﾠ $3,121	 ﾠ $3,219	 ﾠ $844	 ﾠ $933	 ﾠ $1,029	 ﾠ $143	 ﾠ $197	 ﾠ $266	 ﾠ
All	 ﾠHIV+,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤350,	 ﾠexpanded	 ﾠ
Goals	 ﾠ $2,921	 ﾠ $3,016	 ﾠ $3,113	 ﾠ $731	 ﾠ $832	 ﾠ $939	 ﾠ A	 ﾠ A	 ﾠ $51	 ﾠ
EMOD	 ﾠ $7,830	 ﾠ $8,058	 ﾠ $8,288	 ﾠ $2,472	 ﾠ $2,741	 ﾠ $3,025	 ﾠ A	 ﾠ $56	 ﾠ $357	 ﾠ
Macha	 ﾠ $1,263	 ﾠ $1,297	 ﾠ $1,333	 ﾠ $408	 ﾠ $442	 ﾠ $477	 ﾠ $75	 ﾠ $102	 ﾠ $135	 ﾠ
PopART	 ﾠ $4,123	 ﾠ $4,281	 ﾠ $4,442	 ﾠ $768	 ﾠ $905	 ﾠ $1,054	 ﾠ A	 ﾠ A	 ﾠ A	 ﾠ
All	 ﾠHIV+,	 ﾠ
expanded	 ﾠvs.	 ﾠCD4	 ﾠ
≤500	 ﾠexpanded	 ﾠ
Goals	 ﾠ $4,580	 ﾠ $4,739	 ﾠ $4,899	 ﾠ $1,111	 ﾠ $1,256	 ﾠ $1,412	 ﾠ A	 ﾠ $14	 ﾠ $153	 ﾠ
EMOD	 ﾠ $12,796	 ﾠ $13,581	 ﾠ $14,418	 ﾠ $2,103	 ﾠ $2,495	 ﾠ $2,926	 ﾠ A	 ﾠ A	 ﾠ A	 ﾠ
Macha	 ﾠ $941	 ﾠ $976	 ﾠ $1,013	 ﾠ $274	 ﾠ $307	 ﾠ $342	 ﾠ $30	 ﾠ $55	 ﾠ $87	 ﾠ
PopART	 ﾠ $5,723	 ﾠ $5,973	 ﾠ $6,228	 ﾠ $658	 ﾠ $865	 ﾠ $1,091	 ﾠ A	 ﾠ A	 ﾠ A	 ﾠ
‘A’	 ﾠindicates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠfirst	 ﾠdominates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠsecond	 ﾠ(i.e.	 ﾠlower	 ﾠcost,	 ﾠgreater	 ﾠhealth	 ﾠbenefits).	 ﾠ‘B’	 ﾠindicates	 ﾠthe	 ﾠ
policy	 ﾠlisted	 ﾠsecond	 ﾠdominates	 ﾠthe	 ﾠpolicy	 ﾠlisted	 ﾠfirst.	 ﾠ
	 ﾠ
	 ﾠ 	 ﾠ	 ﾠ 22	 ﾠ
Table	 ﾠS9:	 ﾠCost	 ﾠper	 ﾠDALY	 ﾠaverted	 ﾠ(2012	 ﾠUS$)	 ﾠcompared	 ﾠto	 ﾠbaseline	 ﾠstrategy	 ﾠ(CD4	 ﾠ≤350	 ﾠcells/µL	 ﾠ
eligibility,	 ﾠstatus	 ﾠquo	 ﾠaccess)	 ﾠin	 ﾠmodels	 ﾠfor	 ﾠIndia	 ﾠ
Strategy
a	 ﾠ 5	 ﾠyears	 ﾠ 10	 ﾠyears	 ﾠ 20	 ﾠyears	 ﾠ
	 ﾠ	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ
Mishra	 ﾠ(Belgaum)	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ
all	 ﾠHIV+,	 ﾠstatus	 ﾠquo	 ﾠ $1,195	 ﾠ $1,231	 ﾠ $1,267	 ﾠ $437	 ﾠ $466	 ﾠ $497	 ﾠ $173	 ﾠ $198	 ﾠ $228	 ﾠ
FSW	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $831	 ﾠ $857	 ﾠ $884	 ﾠ $252	 ﾠ $271	 ﾠ $291	 ﾠ $71	 ﾠ $85	 ﾠ $102	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW	 ﾠ $2,121	 ﾠ $2,153	 ﾠ $2,186	 ﾠ $886	 ﾠ $929	 ﾠ $976	 ﾠ $348	 ﾠ $390	 ﾠ $440	 ﾠ
FSW	 ﾠelig.,	 ﾠexp.	 ﾠFSW	 ﾠ $1,468	 ﾠ $1,501	 ﾠ $1,534	 ﾠ $508	 ﾠ $539	 ﾠ $573	 ﾠ $176	 ﾠ $202	 ﾠ $232	 ﾠ
all	 ﾠHIV+,	 ﾠexp.	 ﾠFSW	 ﾠ $1,381	 ﾠ $1,417	 ﾠ $1,455	 ﾠ $514	 ﾠ $547	 ﾠ $581	 ﾠ $206	 ﾠ $235	 ﾠ $269	 ﾠ
CD4	 ﾠ≤350,	 ﾠunif.	 ﾠexp.	 ﾠ $13,983	 ﾠ $14,155	 ﾠ $14,327	 ﾠ $7,892	 ﾠ $8,169	 ﾠ $8,458	 ﾠ $5,062	 ﾠ $5,396	 ﾠ $5,773	 ﾠ
all	 ﾠHIV+,	 ﾠunif.	 ﾠexp.	 ﾠ $11,602	 ﾠ $11,764	 ﾠ $11,927	 ﾠ $6,012	 ﾠ $6,249	 ﾠ $6,497	 ﾠ $3,660	 ﾠ $3,927	 ﾠ $4,230	 ﾠ
FSW	 ﾠelig.,	 ﾠunif.	 ﾠexp	 ﾠ $13,360	 ﾠ $13,528	 ﾠ $13,697	 ﾠ $7,377	 ﾠ $7,645	 ﾠ $7,923	 ﾠ $4,605	 ﾠ $4,925	 ﾠ $5,285	 ﾠ
Mishra,	 ﾠno	 ﾠFSW	 ﾠintervention	 ﾠ 	 ﾠ	 ﾠ
	 ﾠ
	 ﾠ	 ﾠ




all	 ﾠHIV+,	 ﾠstatus	 ﾠquo	 ﾠ $1,282	 ﾠ $1,316	 ﾠ $1,350	 ﾠ $512	 ﾠ $538	 ﾠ $566	 ﾠ $219	 ﾠ $241	 ﾠ $266	 ﾠ
FSW	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $655	 ﾠ $673	 ﾠ $690	 ﾠ $213	 ﾠ $225	 ﾠ $239	 ﾠ $65	 ﾠ $73	 ﾠ $83	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW	 ﾠ $1,352	 ﾠ $1,376	 ﾠ $1,401	 ﾠ $439	 ﾠ $462	 ﾠ $488	 ﾠ $124	 ﾠ $141	 ﾠ $161	 ﾠ
FSW	 ﾠelig.,	 ﾠexp.	 ﾠFSW	 ﾠ $1,273	 ﾠ $1,298	 ﾠ $1,323	 ﾠ $368	 ﾠ $389	 ﾠ $411	 ﾠ $98	 ﾠ $112	 ﾠ $129	 ﾠ
all	 ﾠHIV+,	 ﾠexp.	 ﾠFSW	 ﾠ $1,299	 ﾠ $1,325	 ﾠ $1,352	 ﾠ $386	 ﾠ $408	 ﾠ $431	 ﾠ $106	 ﾠ $121	 ﾠ $139	 ﾠ
CD4	 ﾠ≤350,	 ﾠunif.	 ﾠexp.	 ﾠ $7,296	 ﾠ $7,403	 ﾠ $7,511	 ﾠ $3,475	 ﾠ $3,624	 ﾠ $3,781	 ﾠ $1,631	 ﾠ $1,794	 ﾠ $1,982	 ﾠ
all	 ﾠHIV+,	 ﾠunif.	 ﾠexp.	 ﾠ $7,065	 ﾠ $7,171	 ﾠ $7,278	 ﾠ $3,253	 ﾠ $3,397	 ﾠ $3,549	 ﾠ $1,470	 ﾠ $1,623	 ﾠ $1,800	 ﾠ
FSW	 ﾠelig.,	 ﾠunif.	 ﾠexp	 ﾠ $6,543	 ﾠ $6,649	 ﾠ $6,755	 ﾠ $2,834	 ﾠ $2,968	 ﾠ $3,109	 ﾠ $1,274	 ﾠ $1,409	 ﾠ $1,565	 ﾠ
Pruddell	 ﾠ(Bangalore)	 ﾠ 	 ﾠ	 ﾠ
	 ﾠ
	 ﾠ	 ﾠ




FSW	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $1,206	 ﾠ $1,244	 ﾠ $1,283	 ﾠ $249	 ﾠ $275	 ﾠ $303	 ﾠ $11	 ﾠ $24	 ﾠ $40	 ﾠ
MSM	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $2,740	 ﾠ $2,820	 ﾠ $2,903	 ﾠ $690	 ﾠ $752	 ﾠ $821	 ﾠ $95	 ﾠ $128	 ﾠ $169	 ﾠ
FSW	 ﾠ&	 ﾠMSM	 ﾠelig,	 ﾠstatus	 ﾠquo	 ﾠ $2,179	 ﾠ $2,246	 ﾠ $2,314	 ﾠ $513	 ﾠ $562	 ﾠ $614	 ﾠ $61	 ﾠ $85	 ﾠ $116	 ﾠ
all	 ﾠHIV+,	 ﾠstatus	 ﾠquo	 ﾠ $2,573	 ﾠ $2,650	 ﾠ $2,728	 ﾠ $649	 ﾠ $708	 ﾠ $772	 ﾠ $100	 ﾠ $131	 ﾠ $170	 ﾠ
FSW	 ﾠelig.,	 ﾠexp.	 ﾠFSW	 ﾠ $1,173	 ﾠ $1,199	 ﾠ $1,225	 ﾠ $394	 ﾠ $420	 ﾠ $447	 ﾠ $87	 ﾠ $106	 ﾠ $129	 ﾠ
MSM	 ﾠelig.,	 ﾠexp.	 ﾠMSM	 ﾠ $1,856	 ﾠ $1,894	 ﾠ $1,933	 ﾠ $895	 ﾠ $945	 ﾠ $997	 ﾠ $324	 ﾠ $377	 ﾠ $438	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW	 ﾠ&	 ﾠMSM	 ﾠ $1,700	 ﾠ $1,733	 ﾠ $1,766	 ﾠ $878	 ﾠ $920	 ﾠ $964	 ﾠ $350	 ﾠ $398	 ﾠ $455	 ﾠ
FSW	 ﾠ&	 ﾠMSM	 ﾠelig,	 ﾠexp.	 ﾠFSW	 ﾠ&	 ﾠ
MSM	 ﾠ
$1,759	 ﾠ $1,796	 ﾠ $1,834	 ﾠ $795	 ﾠ $841	 ﾠ $890	 ﾠ $264	 ﾠ $310	 ﾠ $364	 ﾠ
IDU-ﾭ‐Manipur	 ﾠ(Churachandpur)	 ﾠ 	 ﾠ	 ﾠ
	 ﾠ
	 ﾠ	 ﾠ




PWID	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $2,787	 ﾠ $2,848	 ﾠ $2,910	 ﾠ $657	 ﾠ $710	 ﾠ $766	 ﾠ $73	 ﾠ $107	 ﾠ $149	 ﾠ
PWID	 ﾠ&	 ﾠex-ﾭ‐PWID	 ﾠelig,	 ﾠstatus	 ﾠquo	 ﾠ $3,535	 ﾠ $3,615	 ﾠ $3,695	 ﾠ $882	 ﾠ $949	 ﾠ $1,020	 ﾠ $152	 ﾠ $197	 ﾠ $250	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠPWID	 ﾠ $1,572	 ﾠ $1,591	 ﾠ $1,610	 ﾠ $871	 ﾠ $911	 ﾠ $951	 ﾠ $427	 ﾠ $487	 ﾠ $553	 ﾠ
PWID	 ﾠelig.,	 ﾠexp.	 ﾠPWID	 ﾠ $1,884	 ﾠ $1,916	 ﾠ $1,948	 ﾠ $655	 ﾠ $706	 ﾠ $758	 ﾠ $98	 ﾠ $143	 ﾠ $196	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠPWID	 ﾠ&	 ﾠex-ﾭ‐PWID	 ﾠ $1,691	 ﾠ $1,720	 ﾠ $1,748	 ﾠ $1,003	 ﾠ $1,046	 ﾠ $1,091	 ﾠ $666	 ﾠ $723	 ﾠ $785	 ﾠ
PWID	 ﾠelig,	 ﾠexp	 ﾠPWID	 ﾠ&	 ﾠex-ﾭ‐PWID	 ﾠ $1,848	 ﾠ $1,882	 ﾠ $1,916	 ﾠ $825	 ﾠ $877	 ﾠ $932	 ﾠ $261	 ﾠ $319	 ﾠ $386	 ﾠ
PWID	 ﾠ&	 ﾠex-ﾭ‐PWID	 ﾠelig,	 ﾠexp.	 ﾠPWID	 ﾠ
&	 ﾠex-ﾭ‐PWID	 ﾠ
$1,981	 ﾠ $2,017	 ﾠ $2,054	 ﾠ $863	 ﾠ $920	 ﾠ $978	 ﾠ $270	 ﾠ $330	 ﾠ $401	 ﾠ
a	 ﾠStrategy	 ﾠrepresented	 ﾠas	 ﾠ<	 ﾠeligibility,	 ﾠaccess	 ﾠ>.	 ﾠFor	 ﾠexample	 ﾠ‘CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW’	 ﾠindicates	 ﾠall	 ﾠadults	 ﾠwith	 ﾠCD4	 ﾠ≤350	 ﾠ
cells/µL	 ﾠare	 ﾠeligible	 ﾠand	 ﾠprioritised	 ﾠexpanded	 ﾠaccess	 ﾠto	 ﾠFSW.	 ﾠ‘unif.	 ﾠexp.’	 ﾠindicates	 ﾠuniformly	 ﾠexpanded	 ﾠaccess	 ﾠto	 ﾠthe	 ﾠgeneral	 ﾠ
population.	 ﾠ
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Table	 ﾠS10:	 ﾠCost	 ﾠper	 ﾠDALY	 ﾠaverted	 ﾠ(2012	 ﾠUS$)	 ﾠcompared	 ﾠto	 ﾠbaseline	 ﾠstrategy	 ﾠ(CD4	 ﾠ≤350	 ﾠcells/µL	 ﾠ
eligibility,	 ﾠstatus	 ﾠquo	 ﾠaccess)	 ﾠin	 ﾠmodel	 ﾠfor	 ﾠVietnam	 ﾠ
Strategy
a	 ﾠ 5	 ﾠyears	 ﾠ 10	 ﾠyears	 ﾠ 20	 ﾠyears	 ﾠ
	 ﾠ	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ 0%	 ﾠdisc.	 ﾠ 3%	 ﾠdisc.	 ﾠ 6%	 ﾠdisc	 ﾠ
Prevtool	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ 	 ﾠ	 ﾠ
FSW	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $1,664	 ﾠ $1,702	 ﾠ $1,740	 ﾠ $531	 ﾠ $557	 ﾠ $585	 ﾠ $143	 ﾠ $161	 ﾠ $182	 ﾠ
MSM	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $2,060	 ﾠ $2,105	 ﾠ $2,151	 ﾠ $749	 ﾠ $783	 ﾠ $818	 ﾠ $254	 ﾠ $280	 ﾠ $311	 ﾠ
PWID	 ﾠelig.,	 ﾠstatus	 ﾠquo	 ﾠ $2,030	 ﾠ $2,076	 ﾠ $2,122	 ﾠ $743	 ﾠ $777	 ﾠ $814	 ﾠ $247	 ﾠ $274	 ﾠ $306	 ﾠ
CD4	 ﾠ≤500	 ﾠelig,	 ﾠstatus	 ﾠquo	 ﾠ $1,241	 ﾠ $1,265	 ﾠ $1,290	 ﾠ $578	 ﾠ $598	 ﾠ $620	 ﾠ $270	 ﾠ $290	 ﾠ $313	 ﾠ
All	 ﾠHIV+	 ﾠelig,	 ﾠstatus	 ﾠquo	 ﾠ $2,055	 ﾠ $2,100	 ﾠ $2,146	 ﾠ $758	 ﾠ $791	 ﾠ $827	 ﾠ $263	 ﾠ $289	 ﾠ $320	 ﾠ
FSW	 ﾠelig.,	 ﾠexp.	 ﾠFSW	 ﾠ $18,779	 ﾠ $19,420	 ﾠ $20,082	 ﾠ $5,004	 ﾠ $5,362	 ﾠ $5,754	 ﾠ $1,270	 ﾠ $1,465	 ﾠ $1,705	 ﾠ
MSM	 ﾠelig,	 ﾠexp.	 ﾠMSM	 ﾠ $11,604	 ﾠ $11,981	 ﾠ $12,369	 ﾠ $3,623	 ﾠ $3,863	 ﾠ $4,124	 ﾠ $1,187	 ﾠ $1,354	 ﾠ $1,555	 ﾠ
PWID	 ﾠelig.,	 ﾠexp.	 ﾠPWID	 ﾠ $10,529	 ﾠ $10,864	 ﾠ $11,210	 ﾠ $3,430	 ﾠ $3,652	 ﾠ $3,893	 ﾠ $1,153	 ﾠ $1,311	 ﾠ $1,502	 ﾠ
CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW,	 ﾠMSM,	 ﾠPWID	 ﾠ $16,614	 ﾠ $17,131	 ﾠ $17,663	 ﾠ $6,190	 ﾠ $6,568	 ﾠ $6,977	 ﾠ $2,392	 ﾠ $2,692	 ﾠ $3,050	 ﾠ
CD4	 ﾠ≤500,	 ﾠexp.	 ﾠFSW,	 ﾠMSM,	 ﾠPWID	 ﾠ $12,708	 ﾠ $13,114	 ﾠ $13,533	 ﾠ $4,415	 ﾠ $4,692	 ﾠ $4,994	 ﾠ $1,631	 ﾠ $1,839	 ﾠ $2,090	 ﾠ
All	 ﾠHIV+,	 ﾠexp.	 ﾠFSW,	 ﾠMSM,	 ﾠPWID	 ﾠ $11,664	 ﾠ $12,042	 ﾠ $12,432	 ﾠ $3,659	 ﾠ $3,901	 ﾠ $4,164	 ﾠ $1,194	 ﾠ $1,361	 ﾠ $1,563	 ﾠ
CD4	 ﾠ≤350,	 ﾠuniformly	 ﾠexpanded	 ﾠ $87,266	 ﾠ $90,024	 ﾠ $92,861	 ﾠ $33,608	 ﾠ $35,635	 ﾠ $37,833	 ﾠ $14,277	 ﾠ $15,932	 ﾠ $17,910	 ﾠ
CD4	 ﾠ≤500,	 ﾠuniformly	 ﾠexpanded	 ﾠ $69,338	 ﾠ $71,610	 ﾠ $73,951	 ﾠ $24,812	 ﾠ $26,372	 ﾠ $28,068	 ﾠ $10,097	 ﾠ $11,303	 ﾠ $12,750	 ﾠ
All	 ﾠHIV+,	 ﾠuniformly	 ﾠexpanded	 ﾠ $63,176	 ﾠ $65,296	 ﾠ $67,481	 ﾠ $20,786	 ﾠ $22,153	 ﾠ $23,644	 ﾠ $7,847	 ﾠ $8,835	 ﾠ $10,028	 ﾠ
a	 ﾠStrategy	 ﾠrepresented	 ﾠas	 ﾠ<	 ﾠeligibility,	 ﾠaccess	 ﾠ>.	 ﾠFor	 ﾠexample	 ﾠ‘CD4	 ﾠ≤350,	 ﾠexp.	 ﾠFSW’	 ﾠindicates	 ﾠall	 ﾠadults	 ﾠwith	 ﾠCD4	 ﾠ≤350	 ﾠ
cells/µL	 ﾠare	 ﾠeligible	 ﾠand	 ﾠprioritised	 ﾠexpanded	 ﾠaccess	 ﾠto	 ﾠFSW.	 ﾠ‘unif.	 ﾠexp.’	 ﾠindicates	 ﾠuniformly	 ﾠexpanded	 ﾠaccess	 ﾠto	 ﾠthe	 ﾠgeneral	 ﾠ
population.	 ﾠ
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